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INTRODUCTION 
This th~sis concerns a melanoma-derived growth regulatory 
factor that inhibited proliferation of several malignant human 
cell lines, and, in particular, a line designated UCT-BR-1, 
which was derived from a human breast cancer metastasis. 
The work is presented in four chapters. Chapter 1 provides a 
review of the relevant literature at the time of writing; 
Chapters 2 and 3 describe the experimental work that was done; 
and in Chapter 4 I discuss the implications of my results for 
current and future work in growth factors. 
Experimental results are presented as Charts (which may be 
Figures or Tables) and the methods and experimental protocols 
that I used are described in the Chart legends and not in the 
main text of the thesis. 
The Appendix contains details of the tissue culture techniques 
and descriptions of the cell lines that were used. Sources of 
the various laboratory materials as well as the methods that 
were employed for the more routine procedures are also 
described in the appendix. 
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ABSTRACT 
A transformed human cell line of neural crest origin has been 
adapted to grow under entirely serum-free conditions. The 
adapted line, termed Bowes/sf, offered a unique opportunity to 
study factors secreted by transformed cells in culture. 
Conditioned medium from the Bowes/sf line paradoxically 
inhibited the growth of a number of human epithelial cell 
lines following a latent period of several days. The human 
breast carcinoma UCT-BR-1 displayed the greatest sensitivity 
to this growth inhibitory effect. 
Preliminary studies indicated that the growth inhibition was 
due to a trypsin-sensitive, partially heat-stable 
macromolecule produced by the Bowes/sf cells. This putative 
molecule was named MDGIF (melanoma-derived growth inhibitory 
factor). In order to facilitate the purification of the MDGIF 
a reliable assay needed to be developed. This was achieved by 
measuring the inhibitory effect on the incorporation of 
radiolabelled thymidine by UCT-BR-1 cells grown in 96-well 
microtiter plates. 
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MDGIF was shown to withstand repeated concentration followed 
by lyophilization and it retained activity following 
extraction into lM acetic acid. A preliminary gel-filtration 
chromatography step gave an estimated molecular weight of 
between 10 000 and 60 000 daltons. Ion-exchange 
chromatography indicated that the MDGIF was positively charged 
while reverse-phase HPLC and phenyl-agarose chromatography 
demonstrated the high intrinsic hydrophobicity of the 
molecule. MDGIF that had been partially purified by 
hydrophobic interaction chromatography was found to contain 
small quantities of TGF-beta. This growth factor is known to 
inhibit cell proliferation in certain circumstances. 
The final characterization involved a combination of acetic 
acid extraction of lyophilized concentrated conditioned 
medium, followed by gel-filtration chromatography. 
Concentration of the conditioned medium, followed by acid 
extraction, increased the specific activity (inhibitory 
units/mg protein) a-fold and resulted in an overall four-fold 
increase in the total yield. The subsequent gel-filtration 
chromatography step demonstrated the presence of several 
molecular species. The material with an estimated Mr of 20 -
25 kilodaltons represented 0.75% of the total protein in the 
conditioned medium and had a specific activity 115-fold 
greater than the starting conditioned medium. This 
partially-purified MDGIF was chosen for further 
characterization. The partially purified MDGIF retained over 
-5-
50% of its activity when heated at 100c C for one-and-a-half 
hours. Time-course experiments showed that the effects of 
partially purified MDGIF on UCT-BR-1 cells were still 
reversible for periods of up to 24 hours. 
Reverse-phase HPLC failed to increase the specific activity of 
the MDGIF preparation. One possible explanation was that 
there were several interacting growth inhibitory factors that 
became separated from one another during the chromatography. 
In summary, this thesis describes the characterization of an 
acid-stable growth inhibitory polypeptide present in medium 
conditioned by Bowes/sf cells. The exact molecular nature of 
this factor (or factors) remains unknown. The multifunctional 
TGF-P appeared to have been responsible for some of the 
observed inhibitory effect. 
Numerous studies of cell growth factors now indicate that the 
final effect of any factor is dependent upon the type of cell 
used as well as the presence or absence of other factors. The 
Bowes/sf cell line which produces an inhibitory factor that 
affects epithelial, but not melanoma cells, remains an 
extremely useful system for the further study of autocrine and 
paracrine cell growth factors. 
' ' 
CHAPTER 1 
LITERATURE REVIEW 
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CHAPTER 1 
INTRODUCTION 
The turn of the century was remarkable for the many 
outstanding scientific discoveries that were made and 
contemporary biological science rests heavily upon the 
achievements of this splendid period. One of the most 
significant of these was undoubtedly the development of 
techniques for the long-term in vitro culture of avian and 
mammalian cells. Medicine, virology, oncology and 
immunology have been particular beneficiaries of the 
contribution of such pioneers in tissue culture as Rous (1), 
Harrison (2) and carrel (3). 
In most of these fields, tissue culture has been used mainly 
as a technique for studying phenomena related rather to the 
interests of the particular discipline than to the 
understanding of cellular function. With concurrent 
conceptual and technical developments in other fields, 
however, tissue culture has now come to provide the 
substrate for the study of the cell itself and "cell 
biology" is a substantive and expanding field of endeavour. 
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A good deal of recent research effort, in cell biology, has 
been spent in attempts to elucidate the mechanisms that 
regulate the rate at which eukaryotic cells proliferate. 
Early workers who used the technique of tissue culture noted 
that cells would not survive for any great length of time in 
culture without the addition of complex biological additives 
such as fetal calf serum, embryo extract or vegetable 
extracts. Our understanding of these phenomena was greatly 
enhanced by the work of such men as Eagle (4) who made a 
systematic study of medium requirements for cell growth in 
vitro, and, more recently, by the observations of Sato (5) 
who pioneered the development of completely defined 
artificial media. 
Thanks largely to the work of these people, tissue culture 
has moved forward, since the beginning of the 1970's, into 
the scientific arena where cellular requirements for 
survival and proliferation are becoming identified and 
characterized. 
During the course of these studies it has become apparent 
that growth of mammalian cells in culture requires the 
presence of complex macromolecular signals known as "growth 
factors" (6). These growth factors are not nutrients; they 
do not function as intermediates in metabolic pathways and 
therefore they neither provide a source of energy for the 
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cell nor do they ultimately become incorporated as 
structural components of the cell. Instead, they exert 
their effects on cells by interacting with specific 
cell-surface receptors. These receptors serve to convert 
this interaction into an intracellular signal. In other 
words, growth factors appear to act in a manner akin to the 
hormones of "classical endocrinology". Growth factors are 
therefore a heterogenous group of non-nutritive 
macromolecules that control the rate of cell division. They 
may elicit one of the following reactions: 
(i) 
(ii) 
(iii) 
increase in the rate of cell division 
decrease in the rate of cell division 
a change in cell phenotype i.e. the appearance and 
behaviour of cells. 
All of the growth factors that have been studied in detail 
are polypeptides. Many, but not all, of these molecules are 
unusually stable and can withstand extremes of temperature 
and pH. For example, epidermal growth factor (EGF) (6,7), 
platelet-derived growth factor (PDGF) (6,8), type alpha and 
beta transforming growth factors (TGFs) (9,10) and type alpha 
and beta interferons (IFN) (11,12,13) are characteristically 
stable in 1 M acetic acid at pH 2.5. All of these molecules 
are fairly heat stable as well. Platelet-derived growth 
factor (PDGF) can be boiled at 100°c for 10 minutes without 
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loss of activity (6). Type beta TGF withstands heating at 
90°C, provided that the pH is kept at 2.5. 
This physico-chemical stability has allowed workers to 
isolate growth factors by using high-resolution purification 
procedures that would damage more labile molecules; for 
example, reverse-phase high-performance liquid 
chromatography (RP-HPLC) has been an invaluable aid in the 
study of growth factors. Many of the growth factors are 
resistant to the denaturing effects of the volatile solvents 
used in RP-HPLC. Because these volatile solvents can be 
completely removed by lyophilization, RP-HPLC is the method 
of choice whenever sensitive biological assays need to be 
performed on chromatography fractions. 
As regards the actual molecular structure, there is probably 
no common feature of note that these factors share. They 
vary in molecular weight from peptides of 6000 daltons to 
proteins of 30 000 daltons as shown in Table 1. 
Like many polypeptides, growth factors appear to be 
synthesized intracellularly as high molecular weight 
precursors (14). Prior to secretion, these precursors are 
cleaved by proteases to form the mature growth factor 
polypeptide. 
Contd./12 
I 
0 
~ 
I 
FACTOR 
EGF 
TGF-a 
TGF-B 
FACTOR IS DEFINED 
OPERATIONALLY ACCORDING 
TO THE FOLLOWING 
CHARACTERISTICS: 
1. Enhances epidermal growth 
and keratinization in vivo. 
2. Causes hyperplasia of 
rabbit corneal epithelium 
in vivo. 
----
). Mitogenic for a wide 
variety of epidermal 
and mesenchymal cells 
in vitro. 
1. Together with TGF-B, 
this factor causes 
transformation of rat 
NRK-49F cells in 
vitro. 
2. Competes with EGF 
for binding to EGF 
receptor. 
). Does not cross-react 
with antibodies to EGF. 
1. Together with TGF-a 
(or EGF), this factor 
causes transformation 
of rat NKR-49F cells 
in vitro. 
2. TGF-8 alone transforms 
murine AKR-2B cells 
in vitro. 
3. Does not compete 
with EGF for binding 
to the EGF receptor. 
MR OF 
MATURE 
POLYPEPTIDE 
(DALTONS) 
6045 
(Murine) 
5616 
(Rat) 
25 000 
(Human) 
STRUCTURE OF 
MATURE 
POLYPEPTIDE 
PRECURSOR 
POL"1 PE PT IDE 
1. Single chain 
polypeptide; 
53 amino acids 
long. 
2. 3 intrachain 
disulphide 
bonds. 
). Contains 
methionine -
therefore is 
cleaved by 
cyanogen 
bromide 
1. Single chain 
polypeptide; 
50 amino acids 
long. 
1217 
amino 
acids 
+130 000 
-daltons 
( 28) 
( 29) 
160 
amino 
acids 
+18 000 
2. 3 intrachain daltons 
disulphide bonds ( ) 
with similar 69 
placement to EGF. 
3. No methionine. 
Not cleaved by 
cyanogen bromide. 
Homodimer; two 
identical 12 SOC 
dalton poly-
peptide ch1<ins 
linked by di-
sulphide bonds. 
Cleavage of these 
bonds destroys 
biological 
activity. 
TABU: 1 
391 
amino 
acids. 
+44 000 
daltons 
( 71) 
HRNA 
(KILO 
BASES) 
4.9 
( 29) 
4.8-5.0 
2.4 
SOURCE OF GROWTU 
FACTOR 
Male mouse sub-
mandibular salivary 
gland is richest 
source - production 
is under the control 
of androgens. 
EGF is also present 
in human tissues -
but there is no 
concentrated organ-
source. 
Produced by malignant 
tumours in vivo end 
transformed cell 
lines in vitro. 
Many different cell 
types make TGF-8. 
The richest source 
GROWTH FACTOR 
RECEPTOR 
180 000 dalton 
transmembrane 
glycoprotein -
with tyrosine 
kinase activity. 
TGF-r:i and EGF 
appear to bind 
to the same 
receptor. 
1. Rec:eptor is 
distinct from 
EGF/TGF-a 
ADDITIONAL 
INFOR:-!ATI ON 
TGF-a and EGF 
are regarded as 
members of the same 
family of poly-
peptides. 
1. TGF-8 not 
relatedto 
EGF or TGF-a. 
is the blood platelet. 
Also produced in 
receptor. 2. TGF-B has 
2.+300 000 dalton both growth 
- kidney 
- placenta 
- transformed cells 
in vitro. 
malignant tumours 
in vivo 
TGF-8 HRNA present 
in all tissues 
except liver ( 71). 
glycoprotein; stimulatory 
probably linked and inhibitory 
to form a complex properties. 
of 600 000 daltons. 
It is a 
bifunctional 
factor. 
FACTOR 
PDGF 
IGF 
FACTOR IS DEFINED 
OPERATIONALLY ACCORDING 
TO THE FOLLOWING 
CHARACTERISTICS: 
1. Th{s factor is stored 
in platelet alpha 
granules; it is present 
in serum, but is absent 
from plasma. 
2. PDGF is mitogenic 
for a number of mesen-
chymal cells in vivo. 
3. PDGF induces a state 
of "competence" in 
resting cells. 
1. Synthesis of IGFs 
appears to depend 
on the presence 
of pituitary 
growth hormones. 
2. IGFs are related, 
structurally, to 
insulin and they 
display a partial 
cross-reactivity 
with the insulin 
receptor; they 
do not cross-
react""with &nti-
bodies to insulin. 
).Generally, insulin 
is more potent in 
producing short-
term metabolic 
effects; IGFs are 
more important in 
promoting growth. 
MR o~· 
MATURE 
POLYPEPTIDE 
(DALTONS) 
Approx. 
30 000 
daltons 
(Human) 
Approx. 
7400 
dal tons 
(Human) 
STRUCTURE 
OF MATURE 
POLYPEPTIDE 
1. Glycoprotein 
2. A heterodimer 
containing 
disulphide 
linked A and 
B chains. The 
~ and ~ poly-
peptides are 
homologous, but 
are clearly 
distinct poly-. 
peptides. Both 
have a Hr of 
approximately 
18 000 daltons. 
IGF-I and II are 
described in 
humans. Both 
are single chain 
polypeptides; 
both of these 
bear homology 
to the A and B 
domain of pro-
insulin. There 
is no homology 
with the C 
domain. 
IGF-I is 70 
amino acids 
long. 
IGF-II is 67 
amino acids 
long. 
(125-129) 
TABLE 1 
PRECURSOR 
POLYPEPTIDE 
B-chain 
precursor 
from endo-
thelial 
cells is 
241 amino 
acids long. 
27281 
daltons 
( 124) 
IGF-I 
130 
amino 
acids 
IGF-II 
180 
amino 
acids 
(125) 
HRNA 
(KILO 
BASES) 
3.5 
SOURCE OF GROWTH 
FACTOR 
1. Blood platelets 
GROWTH FACTOR 
RECEPTOR 
Approx. 180 000 
ADDITIONAL 
INFOR.'IATION 
I. PDGF is 
(endo- Endothelial cells daltons probably thelial 2 · essential for 
cells) J. Cells infected 
with simian ( 124) 
sarcoma virus 
(SSV) 
4. Immature aortic 
smooth muscle 
cells. 
5. Certain trans-
formed cells. 
VARIABLE IGFs are probably 
synthesized by 
IGF-1 many tissues. 
0.9-7.7 
mRNA has been 
IGF-II detected in 
4.9-6.0 liver, heart, 
lung, kidney, 
( 1 29 ) pancreas, spleen, 
small intestine,. 
colon, brain, 
pituitary. 
Possesses tyrosine 
normal wound kinase activity 
IGFs possess 
distinct cell-
surface 
receptors. 
These receptor 
proteins have 
tvrosine kinase 
activity. 
healing. 
2. The oncogene SIS 
codes for a 
PDGF-like mole-
cule. 
3. PDGF acts via 
protein kinase 
C and stimulates 
expression of 
the oncogene 
C-HYC 
IGFs are also 
called 
SOMATOMEDINS. 
In humans, the 
IGF-1 gene maps 
to chromosome 12. 
The gene spans 
>35 kilobase 
pairs (kbp). 
The IGF-II gene 
is on chromosome 
11 and is at 
least 15 kbp 
long. 
(129) 
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A considerable amount of research has been directed at the 
growth factor receptor. These receptors are typically cell 
surface proteins. The growth factor binds specifically to 
this cell surface receptor and this binding normally occurs 
with a very high affinity; the dissociation constant (Kd) 
of the interaction is in the order of 10-10 to 10-12 moles 
per litre. Once the receptor and growth factor are bound 
together the entire complex may be internalized by 
receptor-mediated endocytosis. This process has been 
extensively studied in connection with internalization of 
low-density lipoproteins (15) and is now known to take place 
following the binding of EGF (7) and PDGF (16) to their 
respective receptors. After exposure to PDGF and EGF, 
target cells will express fewer receptors for the growth 
factor when compared with untreated cells. What appears to 
happen is that the target cell synthesises fewer new 
receptors or alternatively, there is less recycling of 
receptors following receptor-factor internalization. In 
this way, a "negative feedback" control is exerted over the 
number of receptors; the more growth factor present in the 
surrounding medium, then the less the number of expressed 
receptors. This phenomenon is termed receptor 
down-regulation. Many different cell-surface receptors are 
probably regulated by a similar mechanism. 
Figure 1 (After Sporn and Todaro (21) ) 
Endocrine 
Paracrine 
Autocrine 
/ 
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A number of the well-studied growth factor receptors appear 
to possess intrinsic enzymatic activity which enables them 
to phosphorylate susceptible tyrosine residues on target 
proteins. These receptors are therefore classified as 
tyrosine kinases. The EGF receptor is a tyrosine kinase 
(17) as are the receptors for PDGF (8), insulin and 
insulin-like growth factor type I (IGF-I) (18,19). A 
distinct possibility exists that phosphorylation of proteins 
at tyrosine may play an important role in the control of 
cell growth. This hypothesis is supported by recent 
research which has demonstrated that many viral and cellular 
oncogenes are now known to code for enzymes which possess 
specific tyrosine kinase activities (19,10). 
A pertinent question conc~rns the route(s) by which growth 
factors reach their respective target cells in vivo. 
Michael Sporn and George Todaro have presented a hypothesis 
which attempts to define three possible pathways (see Figure 
1) (21). In the endocrine pathway, the growth factor is 
secreted into the circulatory system. In this manner, the 
factor is transported to its specific receptor which may be 
localized to a single target organ or, alternatively, may be 
distributed throughout many different organs. The central 
feature of the paracrine pathway is that the growth factor 
engages its receptor after diffusion through the 
interstitial fluid as shown in Figure 1. A requisite of this 
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proposal is that the cells that secrete the growth factor 
must lie in close proximity to the target cells. The 
autocrine pathway is a revolutionary concept which proposes 
that certain cells may synthesize and secrete growth factors 
for which they themselves have receptors. Such cells would 
be partially or even entirely autonomous with regard to 
their growth factor requirements. In their presentation of 
the autocrine hypothesis (21) Sporn and Todaro note that 
transformed cells in culture have reduced growth factor 
requirements when compared with non-transformed cells. A 
newer, modified autocrine hypothesis (22) allows for both 
stimulatory and inhibitory autocrine factors. 
It is not immediately apparent how we might examine these 
ideas with cells cultivated in vitro. Clearly in 
cell-culture systems there is no circulation and there are 
neither "organ sources" nor are there "target tissues". One 
method to reconcile this problem would be to classify growth 
factors as being either exogenous or endogenous. Exogenous 
factors would be those supplied by the serum (typically, 
fetal calf serum) which supplements the culture medium in 
most cases. Exogenous factors could be regarded as 
analogous to endocrine or paracrine growth factors in vivo. 
On the other hand, endogenous factors are made by the cells 
themselves. 
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A number of workers have used serum-free cell culture 
systems to study endogenous factors produced by the cells in 
vitro, on the reasonable assumption that these, if they 
could be shown to be autostimulatory, may be the in vitro 
equivalents of autocrine factors. It should, however, be 
borne in mind that such factors, notwithstanding the 
homogeneity of the cell type in culture, may well be 
paracrine or endocrine in their in vivo action. 
This is an appropriate point at which to define the term 
"conditioned medium", a term that refers specifically to 
cell culture medium, which may or may not be serum-free, in 
which cells have been cultured for a defined period. The 
main features of conditioned medium are that: (a) it 
contains "waste" metabolites produced by the cells; (b) 
some of its nutrients have been depleted; (c) it will 
contain endogenous growth factors. This last attribute has 
recommended the use of conditioned medium as a starting 
point for the purification of growth factors. In most 
instances it has been difficult to prove that the purified 
endogenous growth factor has a direct inhibitory or 
stimulatory effect upon the cells which synthesize it, 
although the matter is receiving considerable attention in 
the literature (22). Conditioned medium is certainly not 
the only source of growth factors. For example, growth 
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factors have also been isolated from extracts of cells in 
culture as well as from whole organ extracts. 
I would now like to discuss in some detail the salient 
features of certain very important growth factors that have 
elicited much excitment in scientific circles. Before 
concluding this introduction, however, two significant 
points need to be made. Firstly, growth factors are best 
seen as being part of a broad family of regulatory 
polypeptides; this group would comprise all polypeptide 
hormones, neuropeptides, paracrine-acting gastrointestinal 
hormones and, of course, cell growth factors. 
Secondly, although it is true that most of our knowledge of 
growth factors has been derived from highly artificial cell 
culture systems, it is nevertheless almost certain that 
these factors do play an essential part in the growth and 
development of normal tissues as well as in wound healing 
(8,23). There is also some evidence that autocrine pathways 
may operate normally in certain tissues during embryogenesis 
(24). These pathways would eventually be "switched off" as 
the embryo matured and would only be reactivated if a 
malignant state were to develop. 
. . 
m u r 1 n e E G F (6) . 
Figure 2 
EGF (Epidermal Growth Factor) is a 53 amino acid polypeptide 
with a molecular weight of 6045 daltons. It exists at a high 
concentration within the submandibular salivary gland of male 
mice. Despite its name, EGF is mitogenic for both epithelial 
as well as mesenchymal cells in vitro. 
EGF has been identified in human tissues and body fluids. 
However, in humans, unlike mice, there is apparently no 
concentrated source of the growth factor. 
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EPIDERMAL GROWTH FACTOR (6,7) 
Murine epidermal growth factor (EGF) is the form of this 
growth factor that has been studied most intensively. This 
is because EGF is present in very high concentrations in the 
male mouse submandibular salivary gland. The term EPIDERMAL 
originates from observations that subcutaneous injections of 
the factor into newborn mice would result in precocious 
opening of the eyelids and premature eruption of the 
incisors. Enhancement of epidermal growth and 
keratinization appeared to be responsible for these 
phenomena. Subsequently, it was demonstrated that EGF was 
mitogenic for corneal epithelial tissue in vivo; EGF was 
found to induce hyperplasia of the corneal epithelium if 
applied topically to experimentally wounded rabbit corneae. 
Fetal lambs treated with EGF in utero manifested a 
proliferative response of the lungs, trachea and oesophagus. 
EGF is mitogenic for both epithelial as well as mesenchymal 
cells in vitro where, characteristically, it will allow 
cells to grow under "serum-starved" conditions. Thus, 
diploid human fibroblasts grow rapidly in EGF-supplemented 
medium containing only 1% serum. (A serum concentration of 
10% is normally used to produce an optimal rate of cell 
growth). EGF has also been reported to increase the 
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saturation density achieved by certain cell types in 
culture. For example, Carpenter and Cohen have demonstrated 
that EGF treatment of human fibroblasts can result in the 
formation of orderly multiple cell layers, in contrast to 
the confluent monolayer which is the normal pattern for 
these cells (6). 
Murine EGF (mEGF) is found in the highest concentration in 
the submandibular salivary glands of the mature male mouse 
where concentrations may be as high as 1 ug per mg of tissue 
(wet weight). Its accumulation in this gland appears to be 
under androgenic control since it has been shown that female 
mice have much lower submandibular gland EGF concentrations 
- approximately 70 ng (0.07 µg) per mg of tissue (wet 
weight). As one might expect, there is a marked difference 
in the EGF content of the saliva in male and female mice 
(1-2 µg/ml and 50 ng/ml respectively). Paradoxically, 
plasma concentrations of EGF 
for both sexes - 1-2 ng/ml. 
in mice appear to be the same 
Murine milk is reported to 
contain 300 ng/ml of EGF. There is no known explanation for 
the high salivary gland EGF in mice, especially the males. 
Recently, Okamoto and Oka (25) have published experiments 
that may shed some light on this phenomenon. Their work has 
suggested that submandibular gland EGF may be essential for 
normal milk production in lactating female mice. 
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EGF has also been identified in humans, but there does not 
appear to be a concentrated source of EGF in any tissue or 
organ. The concentration in human submandibular salivary 
gland (1-2 ng of EGF per gram of tissue (wet weight)) is 
only one millionth that found in the male mouse. The EGF 
concentration that is present in various human body fluids 
is as follows (6): 
Plasma - 2ng/ml; Saliva - 12 ng/ml; Milk - 80 ng/ml; 
Urine - 100 ng/ml. 
The daily urinary excretion of EGF, about 50-60 µg per 24 
hours, is high relative to its low tissue concentration. 
Human urinary EGF is probably identical to a hormone that 
was previously identified as fl-urogastrone, and 
characterized by its ability to inhibit gastric acid 
secretion. 
Savage and Cohen (26) used acid extraction, followed by 
chromatography on Bio-Gel PlO and DEAE-cellulose 
ion-exchange chromatography to purify EGF from male mouse 
submandibular salivary gland. More recently, Burgess et al. 
(27) have purified mEGF on reverse-phase HPLC columns. 
mEGF is a single-chain polypeptide comprising 53 amino 
acids. It has a relative molecular mass (Mr) of 6045 and a 
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pI (isoelectric point) of 4.6. The molecule contains 3 
intrachain disulphide bonds and sedimentation studies 
suggest that it exists as a relatively compact globular 
peptide. Alanine, phenylalanine and lysine do not appear in 
mEGF. Its single methionine residue makes it susceptible to 
cleavage by cyanogen bromide. 
The molecule is both heat and acid stable - attributes that 
greatly facilitate the purification of active growth factor 
under acid conditions. When isolated at neutral pH, mEGF is 
found to consist of a high molecular weight complex 
comprising two molecules of EGF (Mr 6045) non-covalently 
associated with two molecules of an EGF-binding protein (Mr 
29 300). The intact complex, termed High Molecular Weight 
(HMW) EGF, has an Mr of ±74 000. HMW EGF is stable over a 
pH range of 5 to 8. It is of interest to note that the 
EGF-binding protein has proteolytic activity and functions 
as an arginine esterase. The c-terminal arginine of EGF is 
essential for binding to this esterase. It is believed that 
the EGF-binding arginine esterase may be involved in the 
proteolytic processing of precursor forms of EGF. As is the 
case with many other regulatory polypeptides, a "pre-
prohormone" or precursor form of EGF has been identified 
(28,29). The molecule, having an Mr of ±130 000, is very 
large and contains 1217 amino acids. The EGF precursor is 
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The receptor for EGF (Epidermal Growth Factor) is a 180 000 
dalton transmembrane glycoprotein. The internal cytoplasmic 
domain of the receptor possesses tyrosine-specific kinase 
activity. In many respects, the EGF-receptor has come to 
represent a "prototype" for growth factor receptors. 
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therefore more than twenty times larger than the mature 
growth factor. 
Human EGF (hEGF) appears to be structurally similar to mEGF, 
and has a Mr of ±6000. The murine and human polypeptides 
cross-react antigenically. 
The EGF receptor is perhaps the best studied of all the 
known growth factor receptors (17,30,31,32). Human 
fibroblasts possess about 40 000 to 100 000 EGF receptors 
per cell, while the transformed cell line A431 (derived from 
an epidermoid carcinoma) has two to three million EGF 
receptors per cell. The equilibrium dissociation constant 
(Kd) for the interaction of EGF with its receptor is 
probably in the order of 2-4 x 10-1°M. The binding of EGF 
to its receptor appears to result in the specific uptake and 
internalization of the EGF-receptor complex. Following this 
process of "receptor-mediated endocytosis", the internalized 
EGF is degraded in lysosomes (7). 
The EGF receptor is a 180 000 dalton transmembrane glyco-
protein with intrinsic tyrosine-specific kinase activity 
(17,30,31,32). The extracellular portion of the receptor 
contains the EGF-binding domain; the protein kinase domain 
is found intracellularly (see diagram, Figure 3). The major 
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autophosphorylation site appears to be found on the 
c-terminal tail of the molecule. 
In conclusion, EGF can be regarded as a "prototype model" 
for growth factors because it has been studied so 
extensively by many workers. However, much work still needs 
to be done to determine the true physiological role of EGF 
in vivo. 
PLATELET-DERIVED GROWTH FACTOR (6,8) 
Platelet-derived growth factor (PDGF) is a powerful mitogen 
released from the alpha-granules of platelets and its 
discovery stemmed from the observation that serum derived 
from clotted blood has superior mitogenic properties when 
compared with plasma. Balk and co-workers (33) in 1973 were 
among the first to suggest that serum might contain a 
mitogenic factor that was not present in plasma. By 1974, 
Ross et al. (34) and Kohler and Lipton (35) had identified 
the platelet as the source of the mitogenic factor. Ross 
used arterial smooth muscle cells for his assays. He showed 
that whereas these cells proliferated at a normal rate in 
whole blood-derived serum, they remained dormant in serum 
derived from cell and platelet-deprived plasma. 
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PDGF appears to be mitogenic for a number of cells of 
mesenchymal origin, including skin fibroblasts, mouse embryo 
3T3 cells, smooth muscle cells and glial cells. It is 
powerfully chemo-attractant for neutrophils, monocytes, 
smooth muscle cells and fibroblasts and is able to activate 
neutrophils to generate and release active oxygen species. 
These features of PDGF strongly suggest that it has a normal 
physiological role in wound healing. An attractive 
hypothesis is that PDGF may orchestrate the process of 
thrombus "organization" - the well recognized, orderly 
sequence of events by which a blood clot is replaced with 
fibrous tissue. PDGF may also act as an "atherosclerosis 
factor" that is released by platelets that aggregate at the 
site of endothelial damage. Arterial smooth muscle cells 
are thus induced to migrate through the internal elastic 
lamina and to proliferate in the subintima. 
Stiles and co-workers (36,37) have highlighted the role 
played by PDGF during the normal cell cycle. PDGF renders 
the cells "competent" to leave the GO/Gl phase of the cell 
cycle. In Stiles' terminology, PDGF is a "competence" 
factor. It does not initiate DNA-synthesis on its own. 
Other growth factors (termed "progression" factors) are 
necessary for the movement of competent cells into the 
s-phase of the cell cycle. Without the prior action of 
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competence factors, progression factors acting alone are 
similarly ineffective. The insulin-like growth factors 
(IGFs) belong to the category of progression factors. 
The structure of PDGF has been studied in detail in a number 
of laboratories (8,38,39). It is a faily large basic 
glycoprotein (Mr ±30 000 pI 10.2) that is found in two forms 
(8,38). PDGF-I is approximately 31 000 daltons and contains 
7% carbohydrate. PDGF-II is approximately 28 000 daltons 
and contains 4% carbohydrate. The intact PDGF molecule 
comprises two disulphide-linked polypeptide chains, A and B. 
The A chain has an Mr of approximately 17 ooo in PDGF-I and 
approximately 15 000 in PDGF-II. The B chain has an Mr of 
approximately 14 000 in both PDGF-I and -II. Separation of 
the intact molecule into the two individual chains destroys 
its biological activity. 
Some of the best evidence for autocrine control of growth 
has been derived from studies of PDGF. It is now known, 
for example, that cells infected with the Simian Sarcoma 
Virus (SSV) secrete a PDGF-like molecule owing to the 
presence of the v-sis oncogene in the viral genome 
(40,41,42,43,44). This viral oncogene like its counterpart 
in mammalian cells, c-sis, is known to code for a molecule 
that has a PDGF-like structure and can bind to receptors for 
PDGF. Huang, Huang and Deuel (45) demonstrated that an 
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antiserum to PDGF was able to block DNA-synthesis in 
ssv-infected cells. The implication of this work is that 
the cells were being autostimulated by the PDGF-like 
oncogene product of the SSV. Garrett et al. (46) were able 
to show that while SSV-infected cells did not display POGF 
receptors under normal conditions, treatment with suramin (a 
compound which prevents PDGF binding to its receptor) 
allowed the cells to express the PDGF receptor. These 
workers concluded that the virally-induced autocrine 
production of PDGF-like molecules had downregulated the PDGF 
receptors in the cells. Seifert et al. (24), showed that 
cultured aortic smooth muscle cells derived from very young 
rat pups secreted PDGF-like molecules. No such molecules 
were secreted by comparable cultures of smooth muscle cells 
isolated from adult rats. Clemmons et al. (47) had 
previously shown that fetal fibroblast cultures secreted a 
functional homologue of PDGF. Equivalent cultures from 
human donors (post-infancy) did not produce PDGF. The major 
implication of these studies is that autocrine secretion of 
growth factors may serve a physiological purpose during 
embryogenesis. 
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TRANSFORMING GROWTH FACTORS (9,10). 
The transforming growth factors {TGFs) are a family of 
regulatory polypeptides that are operationally defined by 
their ability to induce malignant transformation of 
non-transformed indicator cells in vitro (9,10). The 
features of malignant transformation of cells in culture 
include:-
(a) loss of density-dependent inhibition of growth in 
monolayer culture, 
(b) disruption of the normal growth pattern of the cells 
resulting in the formation of randomly criss-crossed 
multiple cell layers {48) and 
(c) anchorage-independent growth i.e. the ability to 
form growing colonies of cells in soft-agar culture. 
The indicator non-transformed cell line that responds so 
characteristically to the transforming growth factors is the 
NRK-49F rat kidney cell line (48,49). The parental NRK line 
was originally established by Due-Nguyen et al. in 1966 (50) 
and the ability of clone 49F to respond so dramatically to 
transforming growth factors was first reported in the 1970's 
by Todaro and De Laree who undertook much of the pioneering 
work in this field (48,49,51,42,53). 
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Using the NRK-49F cell assay, Roberts and co-workers have 
identified at least two types of transforming growth 
factors; these are designated type alpha (TGF-a) and type 
beta (TGF-P) (9). In the NRK-49F indicator cell system, both 
types of TGFs must be present to induce the characteristic 
malignant transformation (9), whereas TGF-P alone is 
sufficient to initiate transformation of AKR-2B mouse embryo 
cells (54). 
Types a and P TGF are very different from one another. 
TGF-a appears to be mainly associated with malignant cells 
and has been isolated from the conditioned media of many 
transformed cell lines in vitro, as well as from whole 
extracts of transformed cells (55). A high molecular weight 
form of TGF-a has been isolated from the urine of patients 
with disseminated malignancies (56). TGF-a has also been 
described as existing in mouse embryos (57) and it may 
possibly be present in the placenta (58). TGF-P is more 
ubiquitous than TGF-a. The type beta form has been isolated 
from a wide variety of both neoplastic and non-neoplastic 
tissues (59-66). The richest source of TGF-P is the blood 
platelet (64) and it is likely that this growth factor, like 
PDGF, functions in the wound healing response (23). TGF-P 
has also been isolated from human placenta (63) and from 
bovine kidney (65). Many transformed cells in culture have 
been shown to produce TGF-P (9,10,62,71). 
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TGF-a is characterized by its ability to compete with 
epidermal growth factor (EGF) for binding to the EGF 
receptor (9,10). This can be explained by the significant 
degree of amino acid sequence homology that exists between 
EGF and TGF-a as well as by the similar placement of 
intra-chain disulphide bonds in these two molecules. Rat 
TGF-a (or type I TGF) has been sequenced by Marquardt et al. 
(67). It is a 50 amino acid polypeptide of Mr 5616 and it 
has 33% and 44% homology with murine and human EGF sequences 
respectively (67,68). Type-a appears to be made 
intracellularly as a 160 amino acid precursor polypeptide 
(this would have an expected Mr of ±18 000) (69). 
Although TGF-a and EGF belong to the same family of growth 
factors inasmuch as they have a similar structure and they 
share the same cell-surface receptor, the TGF-a molecule 
does not cross-react with antisera specific for EGF (10). 
Another distinguishing feature is the lack of the amino acid 
methionine in the TGF-a molecule (55,70). Methionine occurs 
in both murine and human EGF so that EGF is susceptible to 
cleavage with cyanogen bromide (70) whereas TGF-a is not. 
TGF-P bears no structural similarity to EGF. TGF-P is a 25 
ooo dalton protein that comprises two 12 500 dalton 
polypeptide chains bound by disulphide bridges (62). If the 
disulphide bonds are cleaved, TGF-~ loses all biological 
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activity. Available evidence indicates that TGF-P is a 
homodimer i.e. the two polypeptide chains are identical 
(71). The precursor form of each polypeptide chain comprises 
391 amino acids (71) giving it an estimated Mr of 44 000. 
TGF-P has a unique cell surface receptor and does not bind 
to the EGF receptor (72,73,74). The TGF-P receptor appears 
to be a glycoprotein with a Mr of 280 000 - 330 000 daltons. 
This glycoprotein is probably linked via disulphide bonds to 
form a complex with a Mr of approximately 600 000 
(10,73,74). 
Both TGF-a and TGF-P are very stable molecules that are 
resistant to low pH and to organic solvents (55,62,70). The 
initial steps in TGF purification protocols thus typically 
involve the extraction of tissue or lyophilized conditioned 
medium with lM acetic acid followed by gel-filtration 
chromatography under acid conditions (55,62,70). 
Reverse-phase HPLC has been qsed with such great success 
(75) for the purification of both TGF-a and TGF-P that it 
may fairly be said to have revolutionized the purification 
of these compounds. 
TGF-P displays unique growth inhibitory properties (76) and 
it can function both as a stimulator or an inhibitor of cell 
division; the eventual cellular response depends on the 
surrounding milieu of growth factors as well as the cell 
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type that is being studied (76). This phenomenon will be 
dealt with once more in the section on growth inhibitory 
factors. The widespread distribtuion of TGF-~ as well as 
its unique bifunctional growth-controlling properties imply 
that is may be important in the control of cell division in 
normal tissues. 
Since tumour cells in culture may produce TGF-a and TGF-~, 
it has been suggested (10,22) that these growth factors 
might be involved in the autocrine control of tumour cell 
growth. Evidence also exists to indicate that a TGF-a-
related compound is responsible for the common and 
distressing hypercalcemia that may accompany malignancies 
(77,78). 
THE INSULIN-LIKE GROWTH FACTORS (79) 
Human plasma is known to contain a family of potent growth 
factors that are structurally similar to insulin. These 
insulin-like growth factors (IGFs) are often referred to as 
"somatomedins" since there is evidence to indicate that 
pituitary growth hormone exerts a control over plasma IGF 
levels and that many of the biological effects of growth 
hormone may be mediated by the IGFs (79). 
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The two main IGFs in humans are IGF-I (Mr 7469, 70 amino 
acids long) and IGF-II (Mr 7471, 67 amino acids long). 
IGF-I is now known to be identical with the molecule 
previously designated "somatomedin C". 
The regulation of the synthesis and release of IGF-I is more 
sensitive to growth hormone than is that of IGF-II and 
patients with acromegaly consequently have high IGF-I plasma 
levels whereas their IGF-II levels are normal (80). In 
growth hormone deficiency, however, both IGF-I and IGF-II 
levels are decreased. IGF-I is now believed to be important 
in post natal growth (80,81,82) in contrast to IGF-II which 
is implicated in intra-uterine growth (82,83,84). 
IGFs show approximately 40% homology with the A and B 
domains of human proinsulin (84,85), and IGF-I and II have 
62% amino acid sequence identity with each other. Although 
IGFs do not cross-react immunochemically with insulin, a 
significant degree of IGF binding to the insulin receptor 
does occur. Two subtypes of IGF receptor are described (79) 
- one preferentially binds IGF-I, whilst the other prefers 
IGF-II. The IGF-I receptor is structurally similar to the 
insulin receptor and like the latter, it possesses tyrosine 
kinase activity (18,19). 
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Unlike insulin, which is found free in the plasma, IGFs are 
bound to high molecular weight carrier proteins (79). These 
binding proteins may function to prevent IGFs from exerting 
acute metabolic effects such as hypoglycemia. 
IGFs are important stimulatory growth factors. They are 
well known for their ability to promote radioactive sulphur 
incorporation into the proteoglycans of growing cartilage. 
The elegant work of Stiles et al. (37) has shown that the 
IGFs cooperate with other growth factors, especially PDGF, 
to allow progression through the cell cycle. Massague et 
al. highlighted the importance of IGFs when they showed that 
the transforming activity of TGF-P was dependent on the 
presence of IGFs (86). 
since fibroblasts can produce IGFs in monolayer culture, it 
is possible that many tissues synthesize IGFs in vivo. 
There does not appear to be a concentrated organ-source of 
IGF. 
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GROWTH INHIBITORY FACTORS 
In this review of growth factors, I have emphasized the 
growth-stimulating properties of these molecules. I shall 
devote the remainder of this chapter to growth inhibitory 
factors. These are of special relevance to this thesis 
which deals with the characterization of an inhibitory 
factor. Only those factors that have been 
well-characterized biochemically will be considered in the 
following discussion. This group includes the interferons, 
type-beta transforming growth factor, tumour necrosis factor 
and lymphotoxin. TGF-P, which I have previously discussed 
is unique because of its bifunctional stimulatory and 
inhibitory properties. This emphasizes the concept that 
stimulatory and inhibitory factors should be regarded as 
being part of the same family of growth regulatory 
polypeptides. 
A considerable body of literature has now accumulated around 
the subject of growth factors and their relationships to the 
"chalones" - the putative growth regulatory substances of a 
previous era when definitive purification techniques for the 
characterization of such compounds were not available. 
These issues are discussed in several comprehensive reviews 
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(6,87) and little purpose would be served by repeating them 
here. 
THE INTERFERON SYSTEM (11). 
The interferons (11,12,13,88,89) are a related yet 
heterogenous group of proteins that were first identified as 
cellular secretory products whose synthesis and secretion 
were induced by exposure to viruses., bacteria or other 
foreign macromolecules. 
The interferons are best known for their anti-viral activity 
i.e. their ability to inhibit viral replication in 
susceptible target cells, and as recently as 1980, an 
international group that met under the sponsorship of the 
National Institute of Allergy and Infectious Diseases and 
the World Health Organization (112) agreed that an 
interferon should be defined as a "protein which exerts 
virus nonspecific antiviral activity at least in homologous 
cells through cellular metabolic processes involving 
synthesis of both RNA and protein". Pestka and Baron (88), 
however, as if recognizing the difficulties that may arise· 
when compounds are named or classified exclusively on the 
basis of a single common function, have stated that " ... it 
should not be surprising [when studying interferons] to find 
a homologous molecule with antiproliferative and other 
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activities, but essentially devoid of antiviral activity. 
If such a putative molecule shows extensive homology to 
interferon it should be considered an interferon." These 
comments of Pestka and Baron emphasize the need for 
molecular characterization of all biologically active 
molecules and also draw attention to the now well-known fact 
that interferons may inhibit cellular proliferation in vitro. 
Both non-transformed cells, including embryonic cells, as 
well as transformed cells are sensitive to the 
anti-proliferative property of interferon (11,12,88, 
89,90,91,92,93). Interferons have now been accepted as 
being "negative growth factors" (90). Implicit in this 
definition is the suggestion that interferons may have an 
important regulatory role in controlling growth. If this is 
so, then these molecules are the first well-characterized 
growth inhibitory factors. 
Interferons almost certainly have multiple biological 
functions, and these can be listed as follows:-
(1) Inhibition of viral replication. 
(2) Anti-proliferative effect (decreased rate of cell 
division) • 
(3) Regulation of cellular differentiaation. 
(4) Immunomodulation. 
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Interferons have been studied most fully in the human and 
mouse systems and have been classified into three major 
groups - a, P and 1 - according to their antigenic 
properties. A summary of the formal nomenclature is given 
below: 
Formal Designation 
Alpha interferon 
Beta interferon 
Gamma interferon 
Abbreviation 
IFN-a 
IFN-P 
IFN-1 
Alternative Name 
Leukocyte interferon 
Fibroblast interferon 
Immune interferon 
(11) 
Alpha interferon is the major species produced by 
virus-stimulated leukocytes. The synthesis of IFN-a was once 
regarded as the exclusive function of B lymphocytes, 
macrophages and Null cells, but it has now been shown that 
it can also be produced by T lymphocytes (94). Fibroblasts 
infected with virus produce predominantly the beta type of 
interferon, although some IFN-a will also be made. On the 
other hand, fibroblasts that have been induced with 
synthetic double-stranded RNA (dsRNA) will produce 
exclusively IFN-p. Virus-infected lymphoblastoid cell lines 
are commonly used as a source of interferon. Here the 
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interferon is a mixture of the a and P types, with the beta 
form predominating. Gamma interferon (IFN-1) is a recently 
characterized interferon that is produced by T lymphocytes 
and Natural Killer (NK) cells (94). 
All three types of human interferon are polypeptides in the 
18000-25000 dalton range (11,94). Human IFN-a appears to 
comprise a family of closely related polypeptides. There 
are at least 14 distinct subtypes of IFN-a in the human 
system, each coded for by a different gene (12). In 
contrast to this, there appears to be only one type of IFN-P 
(12) and one IFN-1. (Two forms of IFN-1, differing in 
molecular weight, have been described but this is believed 
to be a result of differences in post-translational 
processing (94)). Both IFN-P and IFN-1 are glycosylated 
whereas the IFN-alpha family is non-glycosylated (95). The 
carbohydrate moieties of the glycosylated interferons appear 
to be essential for the secretion of these molecules from 
the cell (95). 
All IFNs (IFN-P and IFN-1 in particular) are hydrophobic 
proteins. IFN-alpha and IFN-P are stable at pH 2.0 whereas 
IFN-1 is not. In humans, the multiple genes of the a 
interferon family are clustered on chromosome 9 which also 
carries the single gene for IFN-P (94,96). The gene for 
IFN-1 has been localized to chromosome 12 (94,96). 
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At this stage, not much is known about the interferon 
receptor. One of the stumbling blocks has been the 
intrinsic hydrophobicity of the interferon molecule that 
causes considerable non-specific binding in 
equilibrium-binding studies {97). It is believed that there 
is probably more than one type of interferon receptor. In 
humans, at least one of the interferon receptors appears to 
be a product of a gene on chromosome 21 {11,12). In a 
recent paper, Thompson et al. {97) propose that there are 
distinct receptors for IFN-a and IFN-1 and that IFN-P can 
bind to both the a- and the 1-specific receptors. 
Although the induction of interferon synthesis by mammalian 
cells is classically the result of a viral infection, there 
is a group of synthetic, non-viral interferon inducers - the 
ribopolynucleotides. Perhaps the best known member of this 
group is polyriboinosinic acid:polyribocytidylic acid (Poly 
IC). 
It is important to appreciate that the interferons are true 
regulatory polypeptides. They are secreted by specific cell 
populations and they probably reach their target cells by 
the circulation or by local diffusion. Binding to specific 
cell-surface receptors is followed by synthesis of new mRNA 
and protein. Because of the latter process, interferons 
·cannot exert their multiple effects immediately. It 
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typically takes several hours for the full effect to 
manifest (11). 
Interferons exert wide-ranging effects upon the cell's 
biochemistry (12), a full discussion of which would be 
beyond the intended scope of this thesis. There is, however, 
no clear-cut mechanism known that would explain the 
anti-proliferative effect. A recent observation that may be 
of major relevance is that interferons appear to decrease 
the expression of a number of cellular oncogenes in 
transformed cell lines (98). For example, human IFN-~ was 
shown to decrease the transcription of c-myc in Daudi cells 
(99) (Daudi is a lymphoblastoid cell line that is very 
sensitive to the growth inhibitory effects of interferon). 
Transformed mouse 3T3 cells, when treated with murine IFN-~ 
showed a reduction in them-RNA of the oncogene c-Ha-Ras 
(100). Whether these oncogene effects are primary (i.e. an 
immediate result of interferon action) or secondary to the 
slowing of cell division is an important question that is 
yet unanswered. 
As regards the actual anti-proliferative (i.e. growth 
inhibitory) property of the interferons, there would appear 
to be some controversy as to whether this action is 
reversible. I think that most workers regard the action of 
interferon as being a non-toxic reversible form of growth 
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inhibition (11). Certain studies, however, have shown that 
interferons can exert both a cytostatic as well as a 
cytotoxic effect in vitro (91). 
The technical approach that I adopted to study the growth 
inhibitor that I report in this thesis stemmed, in large 
part, from that that had been used to purify interferon. I 
shall, for this reason, discuss the question of interferon 
purification in some detail. On reviewing the literature 
(13,101-108), one cannnot help but echo the words of Robert 
Friedman (11) when he wrote that "almost every method of 
protein separation that has been discovered has been 
employed on the problem of interferon purification ••• " 
Fortunately, new developments and accumulated experience 
have brought order to the field and there are now certain 
specific methods that are widely employed. For example, much 
use has been made of the high intrinsic hydrophobicity of 
the interferons, especially that of IFN-P (109). 
Hydrophobic interactions are responsible for the binding of 
IFN-beta to immobilized amino acids {110), as well as to the 
polychromatic dye Cibacron Blue F3GA (111). The bound IFN-P 
can be released only when the polarity of the surrounding 
mobile phase has been sufficiently lowered. This is 
typically achieved by adding a high concentration of 
ethylene glycol, a molecule which is much less polar than 
water. IFN-a is less hydrophobic than IFN-P and as a result 
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will only bind to immobilized aromatic dipeptides such as 
L-tryptophyl L-tryptophan (110). Human IFN-a also interacts 
with Cibacron Blue F3GA, but in this case the binding 
appears to be primarily electrostatic and is not due to 
hydrophobic interaction (111). These above mentioned 
studies have led to improved rapid purification procedures 
for the interferons. For example, chromatographic methods 
using "Blue-Sepharose" (which contains Cibacron Blue F3GA) 
and "Phenyl-Sepharose" (106,108) have been published in 
recent years for the purification of IFN-P. In both of the 
purification procedures, ethylene glycol is used as the 
eluting agent. 
Reverse-phase high-performance liquid chromatography 
(RP-HPLC) has also been used extensively for interferon 
purification (13). The purification of IFN-a by RP-HPLC was 
one of the first occasions on which this procedure was used 
to isolate a "large protein" (i.e. a polypeptide greater 
than ±12000 daltons) (13,104). RP-HPLC is still the method 
of choice for the purification of IFN-a, and is also used as 
a final step in the purification of IFN-p. The advantage of 
this procedure is that volatile solvents are used. These 
are easily removed by distillation and one is thus able to 
recover the purified interferon entirely salt-free. 
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TYPE BETA TRANSFORMING GROWTH FACTOR 
It has been convincingly demonstrated by Roberts et al. (76) 
that type P transforming growth factor (TGF-P) is a 
bifunctional factor that can either stimulate or inhibit 
cellular division. The final outcome of the addition of 
TGF-P to cells in culture depends on the type of cell and on 
the presence or absence of associated growth factors in the 
culture medium. Evidence for this is as follows: 
(a) TGF-P, in the presence of either EGF or TGF-a, 
stimulates growth of NRK-49F rat kidney fibroblasts 
in soft agar. This is the basis of the assay for 
transforming growth factors. The growth in soft 
agar of transformed cell lines, on the other hand, 
is inhibited by TGF-fl. The human lung carcinoma 
line A-549 is especially sensitive to this 
inhibitory effect. In these experiments, TGF-P 
exerts its inhibitory action at concentrations which 
would normally promote growth of NRK-49F colonies. 
(b) Roberts and her co-workers have transfected a 
cellular myc gene (c-myc) into Fischer rat 
fibroblasts. In the transfected cell line, now 
termed MYC-1, the myc gene is under the control of 
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the Simian virus 40 (SV-40) promoter region. The 
MYC-1 cells are very sensitive to the growth-
promoting action of EGF, and can be stimulated by 
EGF, to form colonies in soft agar. This action is 
antagonized by TGF-P, showing that TGF-P inhibits 
the colony promoting effect that EGF exerts on MYC-1 
cells. 
PDGF alone has no growth controlling action on MYC-1 
cells. However, TGF-P, in the presence of PDGF, 
causes significant stimulation of growth of MYC-1 
cells. TGF-P can therefore function as a 
bifunctional growth factor in the same cell line. 
(c) The inhibitory effects of TGF-P are not confined to 
cells growing in agar but are also seen with certain 
monolayer cell cultures. In other words, TGF-P can 
also inhibit both anchorage-dependent and 
anchorage-independent growth (76). Again, the lung 
carcinoma cell line A-549 is sensitive to this form 
of growth inhibition. In these experiments it was 
noted that TGF-P is cytostatic only; it had no 
effect on cell viability. 
(d) Robert Holley and his fellow workers (113,114) have 
identified an auto-inhibitory growth factor present 
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in the conditioned medium of Green Monkey kidney 
(BSC-1) cells. Although this itself was a novel 
finding at the time, the real significance of the 
discovery was realized only when it was subsequently 
demonstrated that TGF-P and the BSC-1 inhibitory 
factor were identical (115). 
There is therefore a considerable body of evidence to 
support the notion that type P transforming growth factor 
has both stimulatory and inhibitory properties. Roberts et 
al. have stated that "TGF-P is therefore one of the first 
peptide 'Chalones' or growth regulators that has been 
purified to homogeneity" (76). 
LYMPHOTOXIN AND TUMOUR NECROSIS FACTOR 
Lymphotoxin {LT) and tumour necrosis factor {TNF) are 
polypeptides secreted by activated lymphocytes and 
macrophages respectively {116,117). Both molecules appear to 
possess the unique property of being able to kill certain 
malignant cell types in vitro and in vivo without having any 
effect on normal cells (117). These observations have 
obvious therapeutic implications. 
Both LT and TNF have been purified to homogeneity. The 
molecules have been sequenced and their respective genes 
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have been cloned (118-122). Recombinant forms of LT and TNF 
have been produced (119,120,122). These remarkable 
achievements are the result of the enormous advances in 
biotechnology that have occurred in the last ten years. 
Lymphotoxin is a 25 000 dalton glycoprotein (119), while 
tumour necrosis factor is non-glycosylated and has an Mr of 
17 000 (120,121). Although the two molecules are clearly 
distinct from one another, they have a significant degree of 
amino acid sequence homology; the latter might explain ther 
similar biological effects (121). 
In all experiments, normal cells appear to be unaffected by 
either LT or TNF. The sensitivity of malignant cells to 
these factors varies widely. For example, some malignant 
cell lines (such as HeLa cells) are resistant to the factor 
(122). In other transformed cells, TNF has only a 
cytostatic action, while in many other lines, cell lysis 
occurs. 
The normal physiological function of these factors is still 
a matter of debate. It appears likely that they are major 
participants in the response of the immune system to 
invading malignant cells. Playfair et al. {123) have, 
however, proposed that TNF functions to protect the host 
against infections with the parasite Plasmodium sp. and that 
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the tumour necrosis activity is not a physiological function 
of this molecule. Clearly, there is still much work to be 
done in this field. 
·._.1!111.a 
-50-
CHAPTER 2 
INTRODUCTION 
Bowes/sf is a transformed human cell line that has the unique 
ability to grow in the absence of added fetal calf serum. 
This cell line has been observed in the laboratory for a 
number of years and it has been shown that growth in vitro of 
the Bowes/sf cells requires neither polypeptide growth factors 
nor other additives such as transferrin, steroids or thyroid 
hormones. The most plausible explanation for this phenomenon 
is that the Bowes/sf cells produce autocrine stimulatory 
growth factors, thereby circumventing the need for serum 
supplementation. 
To examine this possibility, the effect of Bowes/sf medium on 
the proliferation of serum-dependent cells was tested. Such 
cells, for the purpose of this discussion, can be termed 
"indicator" cell lines. All the indicator lines tested were 
transformed human epithelial lines that required fetal calf 
serum for cell viability, for attachment to the substratum and 
for proliferation. It was expected that the Bowes/sf 
conditioned medium would either stimulate the indicator cells 
or would have no effect. 
Paradoxically, it was found the Bowes/sf medium inhibited the 
growth of a number of the indicator lines, even in the 
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presence of 10% fetal calf serum. This unexpected phenomenon 
was observed even when the conditioned medium was serially 
diluted several-fold making it unlikely that the growth 
inhibition was simply due to nutrient depletion of the medium 
by the Bowes/sf cells. 
This chapter is an attempt to describe the phenomenon of 
growth inhibition and represents, therefore, a pragmatic 
characterization of the factor. Certain essential questions 
are addressed: 
1. 
2. 
3. 
4. 
What effect does the Bowes/sf conditioned medium 
have on the kinetics of growth of serum-dependent 
human cells? 
What effect does the Bowes/sf medium have on the 
morphology (by light microscopy) of the growing 
cells? 
Is the inhibitory action of the Bowes/sf medium a 
consequence of some material added to the medium by 
the cells, or is it due to nutrient depletion? 
If the inhibitor appears to be a secreted material, 
is it dialysable, or is it retained by dialysis 
membranes and by ultrafiltration membranes? 
5. 
6. 
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Could the inhibitory material be a growth regulatory 
polypeptide? 
What is the heat and pH stability of the growth 
inhibitor? 
These questions had to be addressed with an in vitro 
experimental system in which growing cells were used as the 
indicators. In vitro cell culture systems are notorious for 
the many variables they present so that it is difficult in the 
preliminary stages of work of this sort, to give attention to 
all of the questions that arise or to follow all of the many 
leads that tentative experiments suggest. In circumstances 
such as these it is generally preferable to define the primary 
phenomenon operationally and to confine attention to that 
phenomenon without being distracted by secondary questions 
that are best left until the descriptive work has been 
completed. 
In this Chapter, therefore, I avoid consideration of the 
following issues. 
(i) The effect of the Bowes/sf growth inhibitor on 
normal (as opposed to transformed) human epithelial 
cells. 
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(ii) The effect of the growth inhibitor on human cells of 
mesenchymal origin. 
(iii) The action of the growth inhibitor on the Bowes/sf 
cells themselves. 
(iv) The possible presence of growth stimulatory factors, 
the effects of which were hidden (or over-ridden) by 
the growth inhibitor. 
PREPARATION OF BOWES/SF CONDITIONED MEDIUM 
Most of the experiments were performed with serum-free medium 
collected after 24-48 hours of conditioning with Bowes/sf 
cells. The medium was clarified by centrifugation at low 
speed (400g, 10 minutes) and the supernatant was made up to 
10%v/v with fresh fetal calf serum. The mixture was then 
sterilized by filtration through either a 0.45 or a 0.22 
micron filter and was stored in glass bottles at 4°C for no 
longer than 4 days. 
This medium could then be added to cells in culture to 
determine effects on cell growth and morphology. Dilutions of 
serum-supplemented conditioned medium were made with RPM! 
medium containing 10% fetal calf serum (RPMI-10). 
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Fetal calf serum was not added to conditioned medium if it was 
to be concentrated by ultrafiltration or used as the starting 
material for further purification. 
RESULTS 
BOWES/SF CONDITIONED MEDIUM INHIBITED THE GROWTH OF 
SEVERAL HUMAN CELL LINES 
The effect of Bowes/sf conditioned medium on the growth and 
morphology of four human indicator lines was assessed as 
described in Chart 1. After the conditioned medium had been 
in contact with the cells for 9 days, several of the lines 
showed distinct changes in morphology. These changes included 
alterations in cell shape and an increased granularity of the 
cell cytoplasm. UCT-BR-1 (a breast carcinoma) and UCT-CA-2 
(bronchial carcinoma) appeared to have undergone greater 
changes than UCT-SQ-1 (carcinoma of the lip). A431 (epidermal 
carcinoma, rich in EGF receptors) was unaffected. 
After 13 days of exposure to the various dilutions of the 
Bowes/sf medium, the adherent cultures were fixed and stained. 
Dishes that contained Bowes/sf conditioned medium up to a 
dilution of 1:64 showed minimal patchy staining of the rings 
seeded with UCT-BR-1, UCT-SQ-1 and UCT-CA-2 when compared with 
Contd./68 
CHARTS 1, 2, 3 
-f>S-
CHART 1 
INHIBITION OF "INDICATOR" CELL GROWTH BY BOWES/SF 
CONDITIONED MEDIUM 
Bowes/sf conditioned medium inhibited the growth of three out of four human cell lines, viz 
UCT-BR-1, UCT-CA-2 AND UCT-SQ-1. Cell growth was assessed by examining the macroscopic 
stained pattern of the spreading mono/ayer. 
Indicator cells were seeded in eight replicate 35 mm petri 
dishes, each of which was divided into four shallow circular 
chambers by 4 internal rings. Each ring enclosed an area of 
approximately 0.95cm2 (Greiner Cat. No. 627 170) 
Four cell lines (A431, UCT-BR-1, UCT-SQ-1, UCT-CA-2) were used 
and each was seeded in an individual chamber so that each dish 
contained representative cultures of each of the lines. The 
seeding densities (cells per chamber) were as follows: 
A431, 3 x 104; UCT-BR-1, 4 x 104; UCT-SQ-1, 2 x 104; 
UCT-CA-2, 3 x 104. The cells, each in a separate volume of 
medium retained by the shallow rings, were allowed to settle 
. 
and attach overnight at 37°C. The next day the individual 
seeding media were aspirated and the petri dishes were filled, 
each with a dilution of Bowes/sf conditioned medium 
supplemented with 10% FCS. 
Two-fold serial dilutions of Bowes conditioned medium (from 
1:1 to 1:64) were used for 7 of the replicates. The control 
dish (replicate 8) received RPMI-10. 
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CHART 1 
1. Control, RPMI-10 
2. Bowes/sf, diluted 1/32 
3. Bowes/sf, diluted 1/64 
A: A431 
D: UCT-SQ-1 
N: UCT-CA-2 
R: UCT-BR-1 
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CHART 2 
EFFECT OF BOWES/SF CONDITIONED MEDIUM ON 
CELLULAR MORPHOLOGY 
UCT-BR-1, UCT-CA-2, UCT-SQ-1 and A431 cells were grown for 10 days in serial dilutions of Bowes/sf 
conditioned medium. Undiluted Bowes/sf medium inhibited the growth of all 4 cell lines but only 
UCT-BR-1 and UCT-CA-2 were affected by dilutions of the conditioned medium. UCT-BR-1 appeared 
to be the most sensitive indicator line. Cell growth was assessed by phase-contrast microscopy. 
Cells were seeded in 24-well plates at the following 
densities, in RPMI-10. A431, 1.3 x 104 ; UCT-BR-1, 5.5 X 104; 
UCT-SQ-1, 5.5 X 104 and UCT-CA-2, 1 X 104 • After an overnight 
incubation at 37°C, the seeding medium was aspirated, and 1.0 
ml of serial dilutions of Bowes/sf conditioned medium 
supplemented with 10% FCS was added. All dilutions were made 
in RPMI-10. After 3 days of incubation at 37°c the medium was 
aspirated from all the wells and fresh dilutions of Bowes/sf 
conditioned medium or RPMI-10 were added •. Thereafter a fresh 
set of conditioned medium dilutions was added daily. 
The cells were assessed by daily observation with an inverted 
phase contrast microscope. 
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CHART .2 
EFFECT OF BOWES/SF MEDIUM ON 
MORPHOLOGY OF INDICATOR CELLS 
1. UCT-BR-1 cells in RPMI-10. 
5 days after seeding. 
2. UCT-BR-1 cells in 
Bowes/sf conditioned 
medium diluted 1/16 in 
RPMI-10. 5 days after 
seeding. 
3. UCT-BR-1 cells grown 
in undiluted ("neat") 
Bowes/sf medium 
supplemented with 10% 
FCS. 5 days after 
seeding. 
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CHART 2 
4. UCT-BR-1 cells in RPMI-10. 
8 days after seeding. 
5. UCT-BR-1 cells in "neat" Bowes/sf medium 
supplemented with 10% FCS. 8 days after seeding. 
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CHART 2 
6. UCT-BR-1 cells in RPMI-10. 
10 days after seeding. 
7. UCT-BR-1 cells in Bowes/sf medium diluted 1/16. 
10 days after seeding. 
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CHART 2 
8. UCT-CA-2 cells in RPMI-10. 
4 days after seeding. 
9. UCT-CA-2 cells grown 
in Bowes/sf medium 
diluted 1/4 with 
RPMI-10. 4 days after 
seeding. 
10. UCT-CA-2 cells grown 
in undiluted Bowes/sf 
medium supplemented 
with 10% FCS. 4 days 
after seeding. 
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CHART 2 
11. UCT-CA-2 cells in RPMI-10. 
10 days after seeding. 
12. UCT-CA-2 cells in 
Bowes/sf medium 
diluted 1/16 with 
RPMI - 10. 10 days after 
seeding. 
13. UCT-CA-2 cells in 
Bowes/sf medium 
diluted 1/2 with 
RPMI-10. 10 days after 
seeding. 
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CHART 2 
14. A431 cells in RPMI-10. 
5 days after seeding. 
15. A431 cells in Bowes/sf 
diluted 1/4 with 
RPMI-10. 5 days after 
seeding. 
16. A431 cells in 
undiluted Bowes/sf 
medium supplemented 
with 10% FCS. 5 days 
after seeding. 
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CHART 2· 
17. UCT-SQ-1 cells in RPMI-10. 
5 days after seeding. 
18. UCT-SQ-1 cells in 
Bowes/sf medium 
diluted 1/2 with 
RPMI-10. 5 days after 
seeding. 
19. UCT-SQ-1 cells in 
undiluted Bowes/sf 
medium supplemented 
with 10% FCS. 5 days 
after seeding. 
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CHART 3 
GROWTH OF UCT-BR-1 CELLS IN DILUTIONS OF BOWES/SF 
CONDITIONED MEDIUM 
UCT-BR-1 cells were grown for 9 days in Bowes/sf conditioned medium. Cell growth was 
significantly inhibited by both 1:2 and 1:4 dilutions of Bowes/sf conditioned medium when assessed 
at day six and day nine. 
UCT-BR-1 cells were seeded in 6-well tissue culture plates at 
2.5 x 105 cells per well in RPMI-10. The following day the 
medium was replaced with the appropriate dilutions of the 
Bowes/sf harvest fluid. All dilutions were made with RPM! and 
were made up to 10% (v/v) with fresh fetal calf serum. Cells 
were fed on alternate days with fresh medium or with the 
appropriate dilution of Bowes/sf conditioned medium. At the 
individual time points, cells were released from the plates by 
trypsinization and were counted with a haemocytometer. Each 
time point was performed in duplicate~ 
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CHART 3 CONTD. 
Values shown below are means± S.E.M. of duplicate cell counts 
performed on days 3, 6 and 9 of culture. These cell counts 
need to be multiplied by. 10s to obtain the true value per well 
of a 6-well plate. p-values were determined using the 
Student's t-test. 
DAY 
0 
3 
6 
9 
RPMI-10 
(CONTROL) 
2.5[Plating 
density] 
4.1±0.009 
8.83±0.2 
18.5±0 
CELLS GROWN IN 
BOWES/SF 
DILUTED 
TO 1/2 
2.5[Plating 
density] 
3.67±0.22 
NS 
4.68±0.25 
p<0.01 
4.35±0.1 
p<0.005 
NS= Not significant 
BOWES/SF 
DILUTED 
TO 1/4 
2.5[Plating 
density] 
3.53±0.2 
NS 
4.64±0.09 
p<0.005 
7.77±0.2 
p<0.005 
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CHART 3 
Growth of UCT-BR-1 In Bowee/ef medium 
CELL NO x 105 20.---------------------------, 
o.__ ___ ___. ____ __._ ___ __.__ ___ _,__ __ ___. 
0 2 4 6 8 10 
DAYS 
-- Control -4- 1:2 Bowes ----*- 1:4 Bowes 
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the staining of the control dish (Chart 1). The A431 cells 
appeared to have been affected only minimally by the Bowes/sf 
medium. 
A photographic record (Chart 2) was produced in order to 
demonstrate the effect of serial dilutions of Bowes/sf (up to 
1/16) on the indicator cells when present for periods of four 
to ten days. The indicator cells were the same four human 
lines used previously. All these cell lines were inhibited by 
the undiluted ("neat") Bowes/sf medium supplemented with 10% 
FCS. However, only UCT-BR-1 and UCT-CA-2 displayed obvious 
changes in the various dilutions of the Bowes/sf medium. 
After seven days, the UCT-BR-1 cells, in all the dilutions of 
the Bowes/sf medium showed pronounced changes when compared 
with cells grown in the control medium (RPMI-10). These 
changes included an increased cytoplasmic granularity and 
vacuolation as well as a loss of the normal smooth acinar 
pattern that is so characteristic of this cell line. The 
affected cells were no longer as refractile as control 
UCT-BR-1 CELLS grown in RPMI-10. ThehumanbreastcarcinomalineUCT-BR-lwas 
the most sensitive to the degenerative or growth inhibitory action of the Bowes/sf conditioned medium and was 
chosen as the indicator line for all the subsequent experiments. 
A growth study was performed on UCT-BR-1 indicator cells using 
two dilutions of Bowes/sf conditioned medium. (See Chart 3 
for details). Growth of the UCT-BR-1 cells in Bowes/sf was 
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compared with control UCT-BR-1 cells grown in normal RPMI-10. 
The Bowes/sf conditioned medium inhibited the proliferation of the indicator cells. This inhibition was highly 
significant after 6 and 9 days of culture. 
The Bowes/sf medium also inhibited the incorporation of a 
radiolabelled DNA precursor into UCT-BR-1 cells. (see Chart 
4). Uptake of tritiated thymidine (lH-thymidine) into 
UCT-BR-1 cells was measured using an assay adapted from a 
standard laboratory protocol aimed at assessing lymphocyte 
proliferation in microtiter plates (137). The technical 
details of the assay are supplied in the thesis appendix. Serial 
dilutions of Bowes/sf conditioned medium (to 1 in 8) were found to significantly inhibit 3H-thymidine 
incorporation into UCT-BR-1 cells when compared with cells grown in control RPMI-10. ( Chart 4) 
% inhibition of 3H-thymidine uptake was defined as: 
(control cpm -test cpm) x 100 
control cpm 
The polypeptides of the interferon (IFN) family are known to 
be growth inhibitory to a number of different mammalian cells 
in vitro. (See Chapter 1 for the review of the literature). 
The microplate assay was shown to be sensitive enough to 
detect the inhibitory action of human lymphoblastoid IFN when 
serially diluted to 31 i.u./ml. (Chart 5). The inhibitory 
action of IFN could be blocked by a specific polyclonal 
antiserum to interferon (Chart 5) thus demonstrating that the 
Contd. /74 
CHARTS 4, 5 
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CHART 4 
EFFECT OF BOWES/SF CONDITIONED MEDIUM ON ~H-THYMIDINE 
INCORPORATION BY PROLIFERATING UCT-BR-1 CELLS 
UCT-BR-1 cells were grown in 96-well microtiter plates for 72 hours. Serial dilutions of Bowes/sf 
conditioned medium inhibited the incorporation of tritiated thymidine by these cells. 
UCT-BR-1 cells were seeded at a density of 1.8 x 104 cells per 
well of a 96-well microtiter plate. After an overnight 
incubation at 37°, the seeding medium was replaced with 0.2 ml 
of the test medium. Twelve-fold replicates were performed for 
each dilution of the Bowes/sf conditioned medium. Incubation 
of the cells proceeded at 37°C. Eighteen hours prior to the 
termination of the assay, lH-thymidine was added to a final 
concentration of 1 µCi/ml. Following this, the cells were 
harvested as described in the thesis appendix. 
Values shown below are the means± S.E.M. of 12-fold replicate 
counts(cpm) performed in a 96-well microtiter plate. 
p values were determined using Student's t-test. 
RPMI-10 (CONTROL) 16414 ± 332 
Bowes/sf - undiluted 2468 ± 324 p<0.005 
Bowes/sf - diluted 1/2 8881 ± 976 p<0.005 
1/4 12210 ± 497 p<0.005 
1/8 12815 ± 456 p<0.005 
1/16 15420 ± 806 not significant 
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CHART 4 
UCT-BR-1 mlcroplate aeaav 
cpm x103 
18 
16 
14 
12 
10 
8 
6 
4 
2 
0 
1 3 5 7 9 11 13 15 17 19 21 
Fold dilution of Bovves/ sf 
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CHART 5 
THE EFFECT OF HUMAN LYMPHOBLASTOID INTERFERON 
ON }H-THYMIDINE INCORPORATION BY UCT-BR-1 CELLS 
Lymphoblastoid interferon inhibited the incorporation of 3H-thymidine into UCT-BR-1 cells in a 72 hour 
microplate assay. This inhibitory action was blocked by a specific antiserum to interferon. 
Human lymphoblastoid interferon (16 000 i.u./ml - see appendix 
for further details) was diluted to 1000 i.u./ml in RPMI-10 
and was sterile filtered through a Millex-GV unit (Millipore). 
Serial 2-fold dilutions to 1/32 (i.e. 31 i.u./ml) were made 
in RPMI-10. These dilutions were assayed for their ability to 
inhibit 3H-thymidine uptake by UCT-BR-1 cells in a mictotiter 
plate assay. 
INTERFERON CONC.(i.u./ml) 
1000 
500 
250 
125 
62.5 
31.3 
-73-
CHART 5 contd 
CPM 
5020 
5687 
7665 
9718 
10837 
12419 
% l:NHIBITION 
77 
74 
65 
56 
50 
43 
Control 21872 ± 1130 cpm 
All values are means of quadruplicate counts 
A replicate set of microplate wells received an additional 
10.0µl of the sterile 'desalted' interferon antibody 
preparation. This preparation contained antibodies to 
IFN-alpha and IFN-beta (see Appendix). A necessary control 
was the addition of anti-IFN to cells that had been fed with 
plain RPMI-10 only. The anti-IFN was added at time zero. 
INTERFERON CONC. ( i . u. /ml) CPM % INHIBITION 
1000 14697 20 
500 15458 15.9 
250 16279 11.4 
125 15500 15.6 
62.5 18522 -0.8 
31.25 18938 -3.1 
Control (Plus Anti-IFN) = 18370 ± 1553 cpm 
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inhibitory action of the IFN preparation was due to the IFN 
polypeptide and not due to some non-specific effect. 
THE GROWTH INHIBITORY ACTION OF THE BOWES/SF 
CONDITIONED MEDIUM WAS DUE TO A MACROMOLECULE. 
Serum-free Bowes/sf conditioned medium was concentrated either 
in a stirred pressure cell (using an ultrafiltration membrane 
with a 1000-dalton cutoff) or with a hollow fibre apparatus 
using a cartridge with a molecular weight limit of 5000 
daltons. Both the ultrafiltrate and the retentate were made to 
10% (v/v) with FCS and were tested at different dilutions on 
growing UCT-BR-1 cells. A photographic record of the effects 
of the retentate and ultrafiltrate on the indicator cells is 
presented in Chart 6. 
The two methods of concentrating the medium produced very 
similar results. In either case, the retentate appeared to be 
profoundly inhibitory and produced substantial degenerative 
changes in the cells. Conversely, the ultrafiltrate had no 
effect on the microscopic appearance of the cells (Chart 6). 
A growth study of the indicator cells confirmed the above 
results. UCT-BR-1 cells were grown for 200 hours in the 
presence of Bowes/sf conditioned medium preparations that had 
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been treated in a stirred pressure cell using a membrane with 
a limit of 1000 daltons. Both retentate and ultrafiltrate 
were tested. "Whereas the u/trafiltrate had no growth inhibitory action, the dilutions of the Bowes/sf 
retentate were inhibitory as shown in Chart 7. 
Further experiments (results not shown) demonstrated that the 
growth inhibitory factor could be concentrated using an 
ultrafiltration membrane with a 10 000 dalton molecular weight 
limit. Subsequent experiments were performed with this type 
of membrane because it allowed a more rapid concentration. 
It was also demonstrated that the inhibitory activity could be 
retained by a dialysis membrane with a nominal molecular 
weight limit of approximately 12000 daltons. The technique of 
dialysis was employed in the experiments which demonstrated 
the trypsin-sensitivity of the inhibitor. These experiments 
will be described in a later section (see page 76 and Chart 
9) • 
The Bowes/sf growth inhibitor showed a partial but reversible 
susceptibility to heat denaturation. 
Bowes/sf conditioned medium was heated at 65°C for increasing 
periods of time up to twenty-four hours. The heated 
conditioned media were subsequently allowed to cool and were 
diluted with fresh RPMI and made to 10% (v/v) with fetal calf 
serum. These samples were tested on UCT-BR-1 cells in the 
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microplate assay and the effect was compared with that of 
unheated conditioned medium (see Chart 8). 
Heating the Bowes/sf conditioned medium partially reduced its 
inhibitory capacity but failed to abolish it entirely. 
Partial loss of inhibitory activity was maximal at the two and 
the six hour time points. The thermal effect was clearly 
reversible since after 24 hours, the medium appeared to regain 
its full inhibitory activity. 
The Bowes/sf growth inhibitor therefore appeared to·be 
reversibly and partially susceptible to denaturation by 
heating at 65°C for periods up to 24 hours. 
The Bowes/sf growth inhibitor was sensitive to trypsin. 
Serum-free unconditioned RPMI medium or Bowes/sf conditioned 
medium was treated either with trypsin alone or with trypsin 
plus soybean trypsin inhibitor. (See Chart 9}. Treatment was 
carried out at 37°C for 3 hours. The various media (including 
untreated RPMI and Bowes/sf medium) were dialysed against 
distilled water and were evaporated to dryness. Samples were 
reconstituted in RPMI-10 and were assayed for inhibitory 
activity in the UCT-BR-1 microtiterplate assay. 
Contd./88 
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CHART 6 
THE EFFECT OF ULTRAFILTRATION UPON THE ACTIVITY OF THE 
BOWES/SF CONDITIONED MEDIUM: A PHOTOGRAPHIC RECORD. 
Bowes/sf conditioned medium was concentrated several-fold by ultrafiltration. Only the retentate was 
able to produce changes in the morphology of UCT-BR-1 suggestive of growth inhibition. The 
ultrafiltrate had no activity. 
UCT-BR-1 cells were seeded in 24-well plates (Linbro; Flow 
Laboratories) at 5.5 x 104 cells per well. After an overnight 
incubation, the media to be tested were added. 
Bowes/sf medium was concentrated either five-fold in an Amicon 
HIPS hollow fibre cartridge with a M.W. limit of 5000 daltons, 
or twelve-fold in a stirred cell fitted with a 1000-dalton 
cutoff membrane (Amicon, type UM-2). Both the retentate and 
ultrafiltrate were made up to 10% (v/v) with FCS, and were 
then tested, at various dilutions, on the UCT-BR-1 cells. 
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CHART 6 
EFFECT OF ULTRA FILTRATION 
ON BOWES/SF MEDIUM 
1. UCT-BR-1 cells in RPMI-10. 
2. UCT-BR-1 cells in unfractionated Bowes/sf 
medium diluted 1/5 in RPMI-10. 
3. 
4. 
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CHART 6 
Effect of retentate: UCT-BR-1 cells in 
Bowes/sf medium concentrated 5-fold, 
then diluted 1/5. 
/ 
Effect of ultrafiltrate: UCT-BR-1 cells grown 
in Bowes/sf medium filtered through a 5000 dalton 
cutoff membrane. The ultrafiltrate has been 
supplemented with 10% FCS. 
-80-
CHART 7 
GROWTH OF UCT-BR-1 CELLS IN CONDITIONED MEDIUM RETENTATE 
AND IN ULTRAFILTRATE 
Bowes/sf conditioned medium was concentrated by ultrafiltration. The retentate, and dilutions 
thereof, inhibited the growth of UCT-BR-1 cells. The ultrafiltrate was not growth inhibitory. 
Ultrafiltration was performed on conditioned medium that had 
been ultracentrifuged (lOOOOOg; 40 mins) to remove aggregates 
and particulate matter. This was followed by 10-fold 
concentration in a stirred cell fitted with a 1000 dalton 
cut-off membrane. Both the retentate and ultrafiltrate were 
supplemented with FCS prior to testing, and were tested at 
several dilutions. 
The growth of the indicator UCT-BR-1 cells was measured in 
three replicate 24-well plates. On alternate days, the cells 
were fed with fresh conditioned medium preparations. Time 
points were taken at 60, 132 and 204 hours. At each time 
point, all the wells of a plate were treated with trypsin and 
the cells were counted. 
28 
~ 24 
I 
0 
,.... 20 X 
Ji... (l) 16 
..c 
E 
::, 12 C 
Q) 
(.) 8 
4 
0 
0 
-81-
~Control 
A A UM-2 retentate diluted 1/50 
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CHART 8 
THE EFFECT OF HEAT ON THE ACTIVITY OF BOWES/SF MEDIUM 
Bowes/sf conditioned medium was heated at 65°C for increasing periods of time up to 24 hours. 
There was a substantial loss of inhibitory activity after 2 to 6 hours of heating. This was followed by a 
paradoxical recovery of activity at 24 hours. Nevertheless, at all times the heated conditioned medium 
displayed a significant inhibition when compared to control medium. 
2.0 ml aliquots of serum-free 48-hour Bowes/sf conditioned 
medium were heated at 65°c for 30 minutes, 2 hours, 6 hours 
and 24 hours. Serum-free RPM! was also heated at 65°C for 24 
hours. When heating was completed, all the media were diluted 
with an equal volume of RPM! and made to 10% (v/v) with fetal 
calf serum. This was followed by sterile filtration through a 
Millex-GV unit. These samples were tested for growth 
inhibitory activity on UCT-BR-1 cells in the standard 
microplate assay as described in the appendix. Statistical 
analysis using student's t-test was carried out in order to 
compare (i) heated vs. unheated conditioned medium (ii) heated 
conditioned medium vs. control medium. 
MEDIUM TREATMENT 
RPMI NIL 
CONTROL 
RPMI 65°c, 
24 hours 
BOWES UNHEATED 
" 30 min, 65°c 
" 
2 hours, 550c 
" 
6 hours, 550c 
" 
24 hours, 550c 
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CHART 8 contd 
MEAN 
3H-THYMIDINE 
UPTAKE 
±S.E.M. 
20131±433 
22567±512 
12943±394 
14703±272 
17169±472 
16709±322 
13243±263 
0 
-12 
36 
27 
15 
17 
34 
% INHIBITION 
(CONTROL = 0) 
Pl P2 
-
p<0.005 
p<0.025 p<0.005 
p<0.005 p<0.005 
p<0.005 p<0.005 
NS p<0.005 
Pl compares all relevant data with unheated Bowes/sf 
conditioned medium. 
P2 compares all relevant data with the control RPMI-10. 
NS= not significant. 
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CHART 8 
Heating of Bowee/af 
% Inhibition of thymidine incorporation 
40.--~~~~~~~~~~~~~~~~~~~~~---. 
30 
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10 
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CHART 9 
THE EFFECT OF TRYPSIN ON BOWES MEDIUM 
The growth inhibitory effect of the Bowes/sf conditioned medium was destroyed by trypsin. This 
indicated that the growth inhibitor was a protein. The action of trypsin on the growth inhibitor was 
completely blocked by soybean trypsin inhibitor. 
Trypsin (Sigma T 8642, TPCK-treated) and soybean trypsin 
inhibitor (SBTI, Sigma T-9003) were dissolved in PBS, pH 7.4, 
to give final concentrations of 1 mg/ml and 2 mg/ml 
respectively. The 10 ml of serum-free medium to be tested 
received either: 
(i) 
(ii) 
(iii) 
No addition 
40 µg of trypsin alone, 
40 µg of trypsin together with 80µg of SBTI. 
Both serum-free unconditioned medium (RPM!) and serum-free 
Bowes/sf conditioned medium were tested in this system. 
The media were incubated at 37°C for 3 hours in a shaking 
water bath. At the end of the incubation, 80µg of SBTI was 
added to the media that had previously received 40µg of 
trypsin only. 
The media were then dialysed against two changes of 100 
volumes of sterile distilled water. Dialysis membranes with 
nominal molecular weight limits of 12000 daltons were used. 
The dialysed media were evaporated to dryness in a vacuum 
centrifuge, and were reconstituted in 8.0 ml of medium plus 
serum (RPMI-10). 
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CHART 9 contd 
These samples were sterile filtered and were tested for growth 
inhibitory action on UCT-BR-1 indicator cells using the 
standard microtiter plate assay. 
The results below display the 3H-thymidine uptake (in cpm) by 
UCT-BR-1 cells in the presence of the test media. All results 
are shown± S.E.M. and represent the means of quadruplicate 
counts. p values were obtained using Student's t-test. NS= 
Not significant. 
RPMI (unconditioned medium) 
No treatment 
Undiluted 15632±744 
2-fold diln. 16500±518 
Trypsin, 3l°C, 3hr 
Undiluted 16811±690 
2-fold diln. 17448±426 
Undiluted 
2-fold diln 
Trypsin+ SBTI 
3l°, 3hr 
13595±1394 
15276±2067 
Bowes/sf conditioned medium 
No treatment 
5895±830 
8401±461 
Trypsin 3l°, 3hr 
15050±580 
17096±1018 
Trypsin+SBTI 
3l°, 3 hr 
5957±819 
7970±312 
p<0.005 
p<0.005 
NS 
NS 
p<0.005 
p<0.025 
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CHART 9 
Trypetn eueceptlblllty 
- RPMI - Bowes/sf 
cpm x 10-3 
1a---~~~~~~~~~~~~~~~~~~~~~~ ..... 
16 
14 
12 
10 
8 
6 
4 
NIL TRYPSIN 
Treatment 
TRYPSIN + SBTI 
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The growth inhibitory activity of the Bowes/sf conditioned 
medium was abolished by the presence of trypsin (Chart 9). 
Furthermore, this effect of trypsin was blocked by soybean 
trypsin inhibitor. Neither trypsin nor the trypsin inhibitor 
had any effect on the unconditioned control RPMI medium. 
The growth inhibitory action of the Bowes/sf medium appeared 
therefore to be due to the presence of a trypsin-sensitive 
polypeptide. 
THE GROWTH INHIBITORY ACTIVITY OF THE BOWES/SF 
WAS RETAINED FOLLOWING CONCENTRATION OF THE CONDITIONED 
MEDIUM, REMOVAL OF SALTS AND LYOPHILIZATION. 
Holley and co-workers (113) were able to identify a growth 
inhibitory factor in the serum-free conditioned medium of 
BSC-1 cells, a line derived from Green Monkey kidney. The 
attempted chromatographic purification of this factor was 
preceded by the many-fold concentration of the conditioned 
medium. An adaptation of this procedure (113) was used in 
order to assist in the characterization of the Bowes/sf growth 
inhibitor. 
Bowes/sf conditioned medium was concentrated 140-fold in a 
stirred pressure cell fitted with a hydrophilic membrane that 
had a molecular weight limit of 10 ooo daltons. Buffer salts 
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and material with a molecular weight of less than 10 000 were 
removed by a process of constant volume· ultrafiltration. The 
retentate was lyophilized and was tested for growth inhibitory 
activity on UCT-BR-1 indicator cells as described in Chart 10. 
This lyophilisate (referred to as 'fraction A' in the chart) 
was found to retain significant growth inhibitory activity. 
Whereas the UCT-BR-1 cells in the control medium (RPMI-10) had 
multiplied approximately three-fold (from 10 to 32.6 x 105), 
the cells in the undiluted fraction A extract, as well as 
those grown in the extract that was diluted two-fold, had 
actually decreased relative to the original number of cells. 
ANALYSIS BY GEL-FILTRATION CHROMATOGRAPHY 
Bowes/sf conditioned medium was concentrated as described in 
the preceding paragraph and a crude lyophilisate was obtained 
(Fraction A). This was extracted into lM acetic acid and 
chromatographed on a 79 ml bed volume gel filtration column 
(Bio-Gel P60) developed with lM acetic acid. The gel had an 
exclusion limit of 60 000 daltons for globular proteins. 
Thirty fractions were obtained, each of which was tested both 
for growth inhibitory activity on UCT-BR-1 cells and for the 
ability to inhibit tritiated thymidine incorporation by these 
cells (Chart 11). In addition, a photographic record was made 
in order to record changes in cell morphology (Chart 11). 
Fractions 8, 9 and 10, corresponding to a Ve (elution volume) 
Contd./102 
CHARTS 10, 11 
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CHART 10 
GROWTH OF UCT-BR-1 CELLS IN BOWES/SF FRACTION A 
Fraction A was a crude /yophilisate prepared from Bowes/sf conditioned medium by concentration 
followed by a constant volume wash to remove buffer salts and low molecular weight components. 
Fraction A was found to inhibit the growth of UCT-BR-1 cells after seven days in culture. 
Three and a half litres of Bowes/sf conditioned medium was 
concentrated to 25mls by ultrafiltration using a 400 ml 
stirred pressure cell fitted with a hydrophilic YM-10 membrane 
(see Appendix). When this was completed, Tris-Saline 
'Ultrafiltration buffer' pH 7.5 (see Appendix) was added to 
the cell to dilute the conditioned medium concentrate to 400 
mls. This was subsequently reconcentrated to 20 mls after 
which triple distilled water was added to the stirred cell to 
restore the volume to 400mls. Following several cycles of 
"diafiltration" the conditioned medium preparation, which had 
been, in effect, dialysed against distilled water, was 
lyophilized. 66 mg by weight of lyophilizate, termed 
"Fraction A", was obtained from a starting volume of three and 
a half litres of conditioned medium. 
To determine growth inhibitory activity, 10.8 mg of Fraction A 
was added to 15 ml of serum-free RPMI medium and was allowed 
to stir overnight at 4°C. The material, or 'Fraction A 
extract', was clarified by centrifugation and a protein 
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CHART 10 contd 
determination, by the method of Lowry (135), gave an estimate 
of 0.45 mg/ml in the undiluted extract. The latter was made 
to 10% (v/v) with fetal calf serum and was sterilized by 
filtration through a 0.45 micron filter (Millipore HAWP025). 
The extract was tested for growth inhibitory activity on 
UCT-BR-1 cells by the following procedure: 
1. UCT-BR-1 cells were seeded in a 24-well plate (Linbro, 
Flow Laboratories) at 1 x 10s cells per well. 
2. After an overnight incubation at 37°C the medium was 
aspirated and was replaced with 0.5 ml of either RPMI-10 
(control) or Fraction A extract appropriately diluted in 
RPMI-10. 
3. The plate was incubated at 37°c for seven days without 
change of medium. 
4. At the end of this time the cells were released from the 
wells by trypsinization and were counted using a Coulter 
Counter. 
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CHART 10 contd 
GROWTH OF UCT-BR-1 CELLS IN BOWES/SF FRACTION A 
FRACTION A 
EXTRACT 
DILUTION 
CELL NUMBER 
Undiluted 
Diluted 1:2 
1:4 
1:8 
1:16 
1:32 
Control medium 
ESTIMATED FRACTION A CONTENT 
(µgPROTEIN PER ML) 
450 
230 
113 
56 
28 
14 
0 
The cell counts are the averages of duplicate counts. 
The cell number x 104 gives the cell count per well. 
6.38 
8.82 
16.6 
19.5 
26.4 
35.4 
32.6 
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CHART 11 
ANALYSIS OF BOWES/SF GROWTH INHIBITOR BY GEL-FILTRATION 
CHROMATOGRAPHY 
Bowes/sf Fraction A, prepared from Bowes/sf conditioned medium, was extracted into acetic acid 
and was chromatographed on a Bio-Gel P60 column (exclusion limit for globular proteins is 60 000 
daltons). Fractions 8, 9 and 10 were shown to be growth inhibitory to UCT-BR-1 indicator cells by 
three independent methods viz (i) Inhibition of cell growth (ii) Inhibition of 3H-thymidine uptake (iii) 
Alterations in cellular morphology. 
42 mg Bowes Fraction A was extracted into 10 mls of 1 M acetic 
acid by stirring overnight at 4°c. The following day, the 
extract was clarified by centrifugation at 4°C (lOOOg; 15 
minutes). This extract was then concentrated to approximately 
4 ml in an Amicon Smc micro-ultrafiltration system fitted with 
a YM-10 membrane. The concentrated extract was 
chromatographed on a Bio-Gel P60 column (2.3 x 19 cm) in 1 M 
acetic acid. The column was run at 4°C with a flow rate of 
20ml per minute. Column effluent was monitored at 280 nm 
using an ultraviolet spectrophotometer (Uvicord; LKB). 4ml 
fractions were collected. The fractions were each 
freeze-dried, reconstituted in 4mls of distilled water, and 
then re-lyophilized. 
The lyophilized column fractions were each reconstituted in 
2.0mls of tissue culture medium (RPMI-10). These fractions 
were then individually sterilized by filtration thrpugh a 0.45 
micron filter (Millipore HAWP025), and were added to UCT-BR-1 
cells seeded the previous day in 96-well plates (see Appendix 
for microplate assay details) or 24-well plates (Linbro, Flow 
Laboratories) at 1 x 10s cells per well. After 96 hours in 
culture the cells in the 24-well plates were released by 
trypsinization and counted using a Coulter Counter. 
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CHART 11 
DEMONSTRATING THE MO.RPHOLOGICAL CHANGES 
INDUCED BY VARIOUS BIO-GEL P60 FRACTIONS 
- . 
FRACTION 4 
FRACTION 5 
FRACTION 6 
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CHART 11 
FRACTI ON 7 
FRACTION 8 
FRACTION 9 
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FRACTION 10 
FRACTION 11 
FRACTION 13 
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FRACTION 14 
FRACTION 15 
FRACTION 20 
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FRACTION 23 
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of 32-40 mls, inhibited UCT-BR-1 growth as well as the 
incorporation of 3ff-thymidine. Degenerative changes were 
apparent in the indicator cells grown in these fractions, 
especially fraction 9 which also produced the maximal 
inhibitory effect. Both the photographs and the growth 
studies showed that there was a gradation of inhibitory 
activity preceding and also following the major inhibitory 
fractions. 
(N.B. A more definitive gel chromatography step using a 
calibrated column is described in the next chapter.) 
DISCUSSION 
In initial experiments, in which fixed and stained cellular 
monolayers were examined macroscopically, it was clearly shown 
that certain human epithelial cell lines failed to proliferate 
in the presence of diluted Bowes/sf conditioned medium 
supplemented with 10% fetal calf serum (Chart 1). Further 
experiments (Chart 2) demonstrated that one of the indicator 
cell lines, the human breast carcinoma line UCT-BR-1, was the 
most sensitive to the growth inhibitory actions of Bowes/sf. 
In all cell lines tested, growth inhibition and morphological 
changes became apparent only after a latent period of several 
days. An analysis of cell growth kinetics indicated that this 
latent period was probably about 3 days in length. After 6 
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days, the growth inhibitory action was quite apparent (Chart 
3). Because of its sensitivity, UCT-BR-1 was chosen as the 
indicator line to be used for the growth inhibitor assay. 
An assay that was originally designed to test the 
proliferation of human lymphocytes was adapted to measure the 
incorporation of 3ff-thymidine (a DNA precursor) by UCT-BR-1 
cells. 
Serial dilutions of Bowes/sf conditioned medium significantly 
limited the uptake of 3ff-thymidine by UCT-BR-1 cells (Chart 
4). Because this assay was conducted in a 96-well microtitre 
plate it could be used to screen a large number of different 
samples with multiple replicates for inhibition of 
3H-thymidine incorporation. This technique clearly 
demonstrated the marked inhibitory action of an interferon 
preparation on 3ff-thymidine uptake by UCT-BR-1 cells (Chart 
5). Interferon, as indicated in the literature review, 
classically has a growth inhibitory action on a number of 
human cells. 
Growth inhibitory activity in Bowes/sf conditioned medium was 
retained by ultrafiltration membranes with nominal molecular 
weight limits of 1000, 5000 and 10000 daltons. There appeared 
to be little or no inhibitory activity in the ultrafiltrate 
(Charts 6 and 7). In these critical experiments, activities 
were assayed both by assessing cell proliferation as well as 
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by recording changes in cell morphology. The growth 
inhibitory activity, therefore, appeared to be a consequence 
of some macromolecular substance added to the medium by the 
Bowes/sf cells. In a somewhat different system, this 
inhibitory activity was also retained by a conventional 
dialysis membrane (Chart 9). 
The Bowes/sf conditioned medium retained a significant degree 
of inhibitory activity when heated at 65°C for several hours, 
up to one day (Chart 8). Although there was some loss of 
activity after heating, the effect was reversible. 
Treatment of the Bowes/sf medium with trypsin effectively 
abolished the inhibitory activity as assessed by the 
microtiter plate assay (Chart 9). This action of trypsin was 
blocked by the addition of a specific inhibitor of trypsin. 
This demonstrated that the Bowes/sf growth inhibitor was a 
polypeptide. 
Finally, the growth inhibitory activity could be recovered 
after concentration, lyophilization, acetic acid extraction 
and gel-filtration chromatography under acid conditions 
(Charts 10 and 11). The material which eluted from the 
gel-filtration column inhibited both UCT-BR-1 growth, and the 
incorporation of 3H-thymidine by UCT-BR-1 cells and 
furthermore produced the identical morphological changes seen 
in the presence of untreated Bowes/sf conditioned medium. A 
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detailed analysis of yield and% recovery was not undertaken 
at this preliminary stage, nor was the column calibrated in 
order to estimate the molecular weight of the inhibitor. Such 
studies will be described in the following chapter. 
This pragmatic characterization of the growth inhibitory 
phenomenon demonstrated that the Bowes/sf cells secreted a 
polypeptide, that was responsible both for inhibiting the 
growth of UCT-BR-1 cells and for inhibiting 3H-thymidine 
incorporation by these cells. This factor exerted its effect 
only after a latent period of several days. There was, 
however, no proof that a single molecular species was 
responsible for the observed phenomena. A number of different 
polypeptides may well have been involved. Indeed, the heating 
experiment indicated that there was partial loss of activity, 
and this may possibly have been a consequence of the 
inactivation of one or more inhibitors, with the remaining 
inhibitors being heat resistant. The last experiments of the 
series described in this chapter showed that in addition to 
possessing the abovementioned properties, at least one of the 
Bowes/sf growth inhibitors was recoverable after acid 
extraction and gel-filtration. Therefore, at least one of the 
inhibitors had features that were characteristic of a number 
of well-described paracrine and autocrine growth regulatory 
polypeptides including EGF, TGF-a, TGF-~, PDGF (see literature 
review in Chapter 1). 
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In the absence of specific antibodies or c-DNA probes to any 
of the abovementioned factors, it was decided to focus only on 
the characterization of the acid-stable Bowes/sf polypeptides. 
The chapter which follows is a more formal characterization of 
this factor (or factors). 
Definition of specific activity 
Before proceeding with the characterization of any biological 
activity it is important to define that activity in 
quantitative terms. I have therefore defined one unit of 
growth inhibitory activity as that amount that inhibited the 
incorporation of 3H-thymidine by 50% in the standard UCT-BR-1 
microtiter plate assay. 
For the purposes of the characterization process, the specific 
activity will refer to the number of units of inhibitory 
activity per mg of protein. It appeared reasonable to base 
the specific activity on protein content since the preliminary 
experiments had shown the inhibitor to be a polypeptide. 
t ' •. 
I I 
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CHAPTER 3 
INTRODUCTION 
Preliminary studies of the growth inhibitory activity secreted 
by the Bowes/sf cell line demonstrated that the active 
material was an acid-stable trypsin-sensitive polypeptide with 
a molecular weight (based on dialysis and ultrafiltration 
experiments) greater than 10 000 daltons. In this Chapter I 
describe my attempts to characterize the Bowes/sf growth 
inhibitor more definitively. 
The procedure that I eventually adopted in my attempts to 
purify the factor was as follows. Serum-free harvest fluid 
was filtered to remove debris and concentrated approximately 
300-fold by ultrafiltration, dialysed into low ionic strength 
buffer and lyophilized. The dry material was taken up in 
acetic acid and chromatographed successively on a Biegel P-60 
gel-filtration column and on a Cl8 reverse-phase HPLC system. 
Many preliminary experiments went into the development of this 
protocol; I present a brief summary of the relevant results 
in the section that follows the Introduction. Two of the runs 
were reasonably successful in that they went without hitch and 
gave results that were reproducible in the sense that the 
behaviour of the Bowes/sf growth inhibitor was qualitatively 
consistent in both of them. The quantitative results, 
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however, were less reproducible - a fact that is evident from 
the data that I give in the following two tables. 
RUN ONE 
Step 
Conditioned 
medium 
Concentration, 
Diafiltration*, 
Lyophilisation 
Bio-Gel P60 
C18 RP-HPLC 
NOVEMBER 1984 - MARCH 1985 
Total 
Protein 
(mg) 
100 
50 
1 
-0.1 
Specific 
Activity 
Total 
Activity 
(units/mg) (units) 
600 60000 
270 13500 
1785 1785 
1200 120 
*Buffer exchange by ultrafiltration. 
Yield Puri-
(%) 
100 
fication 
(fold) 
1 
23 0.45 
3 3 
0.2 2 
RUN TWO 
Step 
Conditioned 
medium 
Concentration, 
Diafiltration*, 
Lyophilisation 
Bio-Gel P-60 
C18 RP-HPLC 
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JANUARY 1988 - APRIL 1988 
Total 
Protein 
(mg) 
100 
50 
0.75 
0.07 
Specific Total Yield Puri-
Activity Activity fication 
(units/mg) (units) (%) (fold) 
769 76900 100 1 
6290 314500 409 8 
90416 67812 88 118 
11000 770 1 14 
* Buffer exchange by ultrafiltration. 
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Before proceeding with a detailed account of the protocol and 
the results that I obtained, it is appropriate that I discuss 
some of the possible reasons for the differences in yield and 
final specific activity that came from the two runs. 
Run 2 gave a higher recovery of purer inhibitor than did Run 1 
and I attribute this to the following factors. 
Firstly, when I came to perform Run 2 I was much 
more familiar with the system; I was better able to 
plan each stage and, as a result delays were 
minimized and labile stages kept to a minimum. 
Secondly, I found that earlier passage UCT-BR-1 
cells were much more sensitive to the Bowes/sf 
inhibitor i.e. there was intrinsic variation within 
the indicator cells themselves. I therefore used 
the earlier passage UCT-BR-1 as the indicator cells 
in Run 2. 
In the pages that follow I shall consider the results of Run 2 
as the more definitive data set and I shall present the data 
of Run 1 only to provide evidence of qualitative 
reproducibility in chromatographic behaviour. 
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The further characterization of the Bowes/sf inhibitor, as 
described in this chapter, can be divided into three phases. 
Fi~t~ as described in the following section, certain 
preliminary chromatographic analyses were performed. These 
empirical experiments made use of a number of standard 
techniques which are commonly utilized in protein purification 
including ion-exchange chromatography, hydrophobic interaction 
chromatography and reverse-phase high-performance liquid 
chromatography (HPLC). Only the essential findings are 
discussed in this Chapter. 
Secondly, a number of important questions were addressed. These 
included:-
(i) Was it possible to enhance the specific activity of 
the putative growth inhibitor? 
(ii) What was the approximate molecular weight of the 
growth inhibitor? 
(iii) Was there an indication that more than one inhibitor 
may be present? 
(iv) Were there any clues from the published literature 
as to the possible identity of the inhibitor? 
Most of the above questions were addressed within the 
biological limitations imposed by the UCT-BR-1 microplate 
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assay and this somewhat restricted the flexibility of the 
investigations. Ideally, the type of analysis outlined in 
this chapter requires either a specific antibody to the 
molecule of interest or, if the molecule is an enzyme, an 
assay that exploits a catalytic property. 
Thvdly, some observations were made concerning the possible 
biological mechanisms of action of the growth inhibitor. 
For the purposes of clarity and presentation, the putative 
Bowes/sf inhibitor is referred to as MDGIF ("Melanoma-Derived 
Growth Inhibitor") or more simply GI ("Growth Inhibitor"). 
RESULTS 
PRELIMINARY CHROMATOGRAPHIC ANALYSES 
The Bowes/sf growth inhibitory material (MDGIF) was found to 
adhere to cation exchange columns, indicating the major 
inhibitory fraction to be positively-charged (or basic) at 
neutral pH. This was demonstrated both with "conventional" 
ion-exchange resins and with high-performance ion-exchange 
liquid chromatography (HPLC). Ion-exchange chromatography 
was, however, not deemed to be a suitable means of 
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purification and characterization because of the problems 
associated with desalting the column fractions. Since the 
assay of the growth inhibitor depended on demonstrating 
inhibition of proliferation over 72 hours, it was critical to 
remove all buffer salts from the samples. In theory this may 
be achieved by (i) dialysis (ii) constant-volume 
ultrafiltration (iii) gel-filtration chromatography. In 
practice, these procedures were often associated with 
unacceptable losses of activity presumably because the 
fractions concerned had extremely low protein concentrations. 
Furthermore, the problem was compounded by the need to 
sterile-filter all samples prior to assay. 
Although similar problems were encountered with attempts at 
hydrophobic-interaction chromatography, these experiments 
(using Phenyl-Sepharose<R>) strongly suggested that the major 
growth inhibitor was very hydrophobic; the MDGIF bound to the 
Phenyl-Sepharose in a phosphate buffer containing 0.8M 
ammonium sulphate and eluted only when the ammonium sulphate 
was removed and when ethylene glycol (75% v/v) was added to 
the eluting buffer. Because the interferons (see literature 
review) are very hydrophobic, Bowes/sf conditioned medium was 
tested for the presence of interferon. I am grateful to 
Prof. B. Schoub,(National Institute of Virology, Sandringham, 
Transvaal) for performing the interferon immunoassay. No 
interferon immunoreactivity was detected. 
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The hydrophobic material that eluted from the Phenyl-Sepharose 
column was tested for type beta transforming growth factor 
(TGF-P) activity using the NRK-49F assay described in the 
literature review. (Courtesy of Dr. A.B. Roberts, National 
Cancer Institute, NIH, Bethesda, Md.). Active TGF-P was 
detected at - 6-10 ng per mg of MDGIF protein. TGF-P is known 
to be a bifunctional regulator of cell growth (76) and this 
raised the possibility that it alone might be responsible for 
the growth inhibitory activity of the Bowes/sf medium. 
Purified human TGF-P (obtained courtesy of Dr. A.B. Roberts) 
was tested in the UCT-BR-1 72-hour microplate assay, using 
conditions identical to those employed in determining MDGIF 
activity (Methods and results are displayed in Chart 12). 
TGF-P was found to have a bell-shaped dose-response effect on 
3H-thymidine incorporation by UCT-BR-1 cells i.e.both low and 
high doses had a minimal effect on the indicator cells. Only 
concentrations in the range 0.78-25 ng/ml (0.031-lnM) resulted 
in a% inhibition that was greater than 20 (Chart 12). The 
maximum degree of inhibition was -33%, significantly less than 
the inhibition obtained in many preliminary MDGIF assays. 
Therefore, although purified TGF-P was inhibitory in the 
microtiter plate assay, it was unable, at the doses used, to 
achieve the same degree of inhibition demonstrated by MDGIF. 
This strongly suggested that TGF-P alone was not responsible 
for the phenomenon described in the previous Chapter and that 
there must be at least one other polypeptide factor involved. 
Contd./117 
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CHART 12 
THE EFFECT OF PURIFIED TGF-BETA ON UCT-BR-1 CELLS IN THE 
STANDARD MICROTITER PLATE ASSAY. 
Purified human TGF-beta had a significant inhibitory action on UCT-BR-1 cells using the 3H-thymidine 
uptake assay. Maximal inhibition was 33%, and this occu"ed in the 1-6 ng/ml ( - 100pM) range. 
Concentration 
of TGF-~ in 
the medium (Ng/ml) 
100 
50 
25 
12.5 
6.25 
3.125 
1.56 
0.78 
0.39 
0.2 
0.1 
Mean cpm 
(± SEM) 
31384±1085 
31423±212 
27911±555 
27280±793 
26703±668 
25992±911 
26417±689 
29733±916 
32329±887 
36366±1221 
38022±1236 
Control : 38591 cpm ± 4774 
% Inhibition p value 
19 <0.05 
10 <0.05 
28 <0.01 
29 <0.01 
31 <0.025 
33 <0.005 
32 <0.005 
23 <0.025 
16 -0.05 
6 NS 
1.5 NS 
NS= Not significant. p values determined by Student's t-test. 
NB. TGF-beta concentration of 200 ng/ml or greater did not 
appear to produce any further inhibition. 
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CHART 12 
Effect of TGF-beta 
% inhibition of thymidine incorporation 
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DETERMINATION OF SPECIFIC ACTIVITY 
As outlined in the previous Chapter, one unit of MDGIF 
activity is that quantity of a particular MDGIF preparation 
that inhibits 3H-thymidine incorporation into UCT-BR-1 cells 
(seeded in microtiter plate wells) by 50%, over a 72 hour 
period. Furthermore, it was decided that specific activities 
were to be defined in terms of units of activity per mg of 
protein. In order to do this, the following protocol was 
adopted: 
Step One 
(i) An aliquot of MDGIF preparation was lyophilized and 
was then reconstituted in a minimal volume of 4mM 
HCl. 
(ii) 
(iii) 
This was subsequently diluted 10-fold in PBS, pH 7.4. 
The protein concentration of this aliquot was 
determined by standard techniques, as described in 
the appendix. 
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Step Two 
( i) An identical aliquot of the MDGIF preparation was 
lyophilized and was reconstituted in 4mM HCl 
containing bovine serum albumin (BSA) at 1 mg/ml. 
This HCl/BSA solution is referred to as "HB". 
(ii) The HB sample was diluted 10-fold in sterile RPMI 
medium containing 10% fetal calf serum. In this 
manner, the amount of MDGIF protein in the sample 
could be quite accurately determined. The low pH of 
the HB was sufficient to sterilize the sample and 
this precluded filtration procedures. 
(iii) Finally, the reconstituted material was serially 
diluted in RPMI-10 and each dilution was tested in 
quadruplicate in the standard microplate assay, at a 
final volume of 0.1ml per well. 
(iv) The response in the UCT-BR-1 microtiter assay was 
defined in terms of% inhibition of 3H-thymidine 
uptake relative to control UCT-BR-1 cells that had 
received only RPMI-10. 
% Inhibition= Control cpm - Test cpm x 100 
Control cpm 1 
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step Three 
(i) A dose-response curve was constructed in which the 
percentage inhibition of 3ff-thymidine incorporation 
was plotted as a function of the protein 
concentration of a particular MDGIF preparation. 
This relationship could be linearized by plotting 
the legit transform of the% inhibition (or of the 
thymidine incorporation expressed as a fraction of 
the control value) as a function of the logarithm of 
the protein concentration. 
The legit transform of a value 'y' is defined as: 
legit (y) = log (y/100 - y). 
(ii) One unit of activity was determined, either by 
interpolation or by extrapolation, as that point 
where the logit was equal to zero (i.e. y = 50% or 
0. 5) • 
The legit transformation is commonly used to 
linearize the dose-response curve of 
complement-mediated immune hemolysis (138). 
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FURTHER CHARACTERIZATION OF MDGIF 
The MDGIF displayed the characteristics of molecule (or a 
number of distinct molecules) with a molecular weight(s) in 
excess of 10 000 daltons. This conclusion was based upon 
several ultrafiltration and dialysis experiments, as described 
in Chapter 2. 
It therefore appeared reasonable to attempt to concentrate the 
Bowes/sf by membrane ultrafiltration. This approach had been 
adopted by Holley and co-workers in the characterization of 
the TGF-beta/BSC-1 growth inhibitory factor (113,114). 
Accordingly, 6 to 7 liters of pooled Bowes/sf conditioned 
medium, which had been stored in the presence of 0.05% sodium 
azide, was concentrated to 700 mls using a Millipore (Minitan) 
concentrator fitted with a set of membranes, each of which had 
a molecular weight "cut-off" limit of 10 000 daltons. Further 
concentration was completed in a stirred pressure cell, and 
this was followed by constant volume ultrafiltration (commonly 
referred to as "diafiltration") to remove the sodium azide, 
phenol red and buffer salts. The material was then 
lyophilized. 
Typically, six to seven liters of serum-free Bowes conditioned 
medium yielded 250-350 mg (by weight) after concentration, 
diafiltration and lyophilization. This material, which 
-121-
represented the crude macromolecular retentate of the 
ultrafiltration process was termed "Fraction A" and was found 
to contain - 0.18 mg of protein per mg of dry material. (The 
method of Fraction A preparation is described in detail in 
Chart 13). Therefore, the yield of protein from 6-7 liters of 
conditioned medium was of the order of 50 mg. The protein 
concentration of unconcentrated Bowes/sf conditioned medium 
was previously estimated to be - 17 mg/litre. (This 
estimation was carried out by determining the protein content 
of dialysed 48-hour conditioned medium). Therefore 6-7 litres 
of medium should contain - 100 mg of protein. Clearly, there 
was loss of protein, amounting to about 50% of the starting 
material, in the concentration and lyophilization process. 
The protein content of the conditioned medium ultrafiltrate, 
previously shown to have no growth inhibitory activity, was 
very low - less than 2 mg per liter. Therefore, of the 50% 
loss of protein that occurred during the preparation of 
fraction A, less than 12% was lost in the ultrafiltrate whilst 
the remainder (i.e. 38% or more) probably represented 
non-specific and unavoidable adherence of protein to membranes 
and to other surfaces. The loss of protein by this latter 
mechanism had been anticipated and it was for this reason that 
the tangential ultrafiltration mechanism, that the "Minitan" 
system provided, was chosen in preference to other methods. 
Furthermore, hydrophilic ultrafiltration membranes were 
utilized at all times in order to further minimize losses. 
Contd./126 
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CHART 13 
PREPARATION OF 'FRACTION A'. 
"Fraction A" represented a crude preparation of macromolecular material that contained the inhibitor 
present in the serum-free conditioned medium. It provided the first step in the attempt to further 
characterize the inhibitory factor. 
The Bowes/sf conditioned medium, which had been collected and 
stored at 4°C in the presence of 0.05% NaN3 , was first 
concentrated about ten-fold on a Millipore Minitan<R> 
concentrator that is described in the Appendix. During any 
'run', 6 to 7 litres of conditioned medium would be 
concentrated to about 700 to 800 mls. 
Further concentration was carried out using a 400ml stirred 
pressure cell (Amicon) fitted with a YM-10 membrane. The 
±800ml of conditioned medium from the Mmftan was concentrated 
to give 20mls, making the total concentration factor 300-fold. 
This was followed by a process of diafiltration that had been 
adapted from the method used by Holley et al. (113). These 
·workers had employed this procedure for the purification of 
the BSC-1 inhibitor/TGF-beta. The protocol was as follows: 
The 20 ml of conditioned medium was diluted to 400ml with 
tris-buffered saline or "ultrafiltration buffer" (Appendix). 
This was reconcentrated to ±20 ml and was then subsequently 
diluted five-fold to 100ml with sterile triple-distilled 
water. Re-concentration to 25mls followed. The ionic 
strength of the sample at this stage would have been 
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CHART 13 contd 
equivalent to 0.03M NaCl; the azide, phenol red, as well as 
the other RPMI components would have been reduced to 1/100 of 
their initial concentration. 
The 25ml of diafiltered material was then removed from the 
stirred pressure cell and immediately lyophilized. This 
material was termed "Fraction A". The ultrafiltration 
membrane used for the concentration process was also removed 
from the cell and washed overnight in 20 ml of lM acetic acid 
to release adherent material. 
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CHART 14 
CALCULATION OF THE SPECIFIC ACTIVITIES OF 
VARIOUS MDGIF PREPARATIONS 
LogjLogit Plots were used to transform the Inhibitory dose-response curve of the Bowes/sf inhibitor 
into a linear function. 
a, 14(af-BOWES/sf 
C 1.2 .... 
-0 • 
.... C 
E 0 • 8 
"' .... 
..c ..µ 
+J 0 • 4 
l 
0 
CL 0 
4- l 
0 0 
0 
-. 4 
+J C 
.... .... 
en 
-. 8 a 0 2 ...J 1 4 8 20 
. Fold-dilution of 
-BOWES/sf medium 
a, 14Cb) Fraction A 
C 
.... 
-0 • 0 
.... C 
E 0 
"' .... 
..r:. +J 
-. 5 ., 0 
l 
0 
CL 
4- l 
-1 0 0 
0 
.µ C 
.... .... 
01 
-1. 5 0 
_J 1 10 100 
Protein Cug/ml) 
-125-
0 14(c) Fraction B 
( 
·r-1 
u • 0 
·r-1 ( C 
E 0 
"- .... 
.r. .µ 
.µ 0 
l -. 5 
0 
a_ 
~ l 
0 0 
0 
.µ ( -1 
·r-1 .... 
en 
0 0.1 1 10 _J 
Protein (u9/ml) 
-126-
The specific activity of untreated Bowes/sf conditioned medium 
was determined from the dose-response curve previously 
displayed in Chapter 2 (Chart 4 ). A log/legit plot of this 
data indicated that 200 µl of a 2.46-fold dilution of Bowes/sf 
conditioned medium produced 50% inhibition of 3ff-thymidine 
incorporation by UCT-BR-1 cells. (This data is displayed in 
Chart 14a). Therefore it was calculated that 1 ml of Bowes/sf 
conditioned medium, representing - 16µg of protein, contained 
12.3 units of inhibitory activity i.e. 1 mg contained 769 
inhibitory units. Similarly it was possible to calculate the 
specific activity of the Fraction A protein by the previously 
described methods. (This data is displayed in Chart 14b). 1 mg 
of 'Fraction A' protein represented therefore, approximately 
6290 inhibitory units. 
Therefore, this characterization yielded the following data: 
Amount of Specific Activity Yield 
Protein (mg) (Inhibitory units/ {Total Units) 
mg Protein) 
Untreated 
Bowes/sf 100 769 76900 
Conditioned 
medium 
Bowes/sf 50 6290 314500 
"Fraction A" 
Preparation 
-127-
This demonstrated that there was not only an approximate 
a-fold enhancement of specific activity, there was in addition 
an unexpected four-fold increase in the total number of 
inhibitory units present. 
In the purification of a biologically active macromolecule, 
one usually finds that the yield decreases with each 
consecutive stage of purification. However, this does not 
necessarily have to be the case and there are several 
plausible reasons why this might be so: 
(A) Certain growth regulatory polypeptides e.g. TGF-~ 
(140) are secreted mainly in an inactive or latent 
form and are known to undergo activation during the 
purification process. Activation of latent growth 
regulatory factors could occur either under acid 
conditions (140) or as a consequence of the actions 
of specific proteolytic enzymes. 
(B) The crude conditioned Bowes/sf medium may have 
contained either growth stimulatory factors or 
factors which interfered with the mode of action of 
the growth inhibitor, and such factors might have 
been removed during the initial purification steps. 
In the case of the Bowes/sf conditioned medium, 
there was no evidence that the conditioned medium 
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ultrafiltrate possessed growth stimulatory activity. 
However, the UCT-BR-1 microplate assay, conducted in 
the presence of 10% FCS, was designed to detect 
growth inhibition and not stimulation. Therefore, 
the possible co-existence of growth inhibitors and 
growth stimulators could not be ruled out. 
In the next stage of the characterization, the Bowes/sf growth 
inhibitory material was chromatographed on a gel-filtration 
column under acid conditions (Chart 15). Lyophilized MDGIF 
Fraction A was extracted overnight in lM acetic acid and the 
extract was chromatographed on a Bio-Gel P-60 column in the 
presence of acetic acid. This column had previously been 
calibrated with several standard molecular weight markers 
(Chart 15). The fractions were analysed for growth inhibitory 
activity using the UCT-BR-1 microtiter plate assay. Two 
peaks of inhibitory activity were obtained (see Chart 15), one 
with a maximum at fractions 15 to 18 (peak 1) and the other 
with a maximum at fractions 26 to 30 (peak 2). The degree of 
overlap between these two peaks varied. On some occasions 
they were clearly separate, whilst on others, two broadly 
overlapping peaks were observed. (Chart 15 displays data from 
two individual gel-filtration chromatography runs.) According 
to the elution positions of the various molecular weight 
markers the maximum of inhibitory peak 2 suggested a molecule 
with a molecular weight of the order of 20-25000 daltons, 
whereas the maximum of peak 1 suggested material with a 
Contd./132 
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CHART 15 
Profile of inhibitory material eluting from Bio-Gel P60 gel filtration column. Fractions from peak 2 were 
pooled and /yophilized. This material was termed 'Fraction B'. The data from two individual 
chromatograms is displayed (Runs 1 and 2). 
The lyophilisate of the material concentrated on the stirred 
pressure cell (Fraction A) was extracted overnight at 4°C in 
-40ml of lM acetic acid. The extract was clarified by 
centrifugation and was then combined with the 20ml of lM 
acetic acid that had been used to wash the YM-10 
ultrafiltration membrane. This gave some 50 to 60 ml of lM 
acetic acid extract which was lyophilized and reconstituted in 
15 mls of lM acetic acid. This 15 ml of concentrated extract 
represented the starting material for Bio-Gel P60 
chromatography. 
The 15 ml of acetic acid - extracted material was 
chromatographed on a 89 x 2.6 cm (470 ml bed volume) column 
that had been equilibrated in lM acetic acid. The column was 
run at room temperature using a gravity-induced flow rate of 
10 mls per hour (1.88 mls/hour/cm2). A Mariette flask kept 
the flow rate constant. Prior to this analysis the column had 
been calibrated under identical conditions using standard 
molecular weight markers. These included (i) Blue dextran 
(ii) Albumin (67000 daltons) (iii) Ovalbumin (43000 daltons) 
(iv) Ribonuclease A (13700 daltons) and (v) Insulin (6000 
daltons). The albumin was found to co-elute with the void 
volume marker viz. Blue dextran. 
7.5 ml fractions were collected. 0.5 ml aliquots were removed 
from each fraction and lyophilized. These samples were 
subsequently reconstituted in 0.1 of 4mM HCl containing lmg/ml 
BSA (Sigma) and were transferred to 0.9 ml of RPMI-10, for 
assay in the UCT-BR-1 microplate procedure. 
-130-
CHART 15 
Protein Profile 
of Bio-Gel P60 
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CHART 15 
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molecular weight equal to or in excess of 50000 daltons. It 
was conceivable that the material in peak 1 therefore 
represented dimeric or perhaps multimeric forms of the growth 
inhibitory molecule. For this reason, it was decided to 
further characterize only peak 2. Hence, these fractions 
were pooled and lyophilized. The material obtained by this 
procedure was termed "fraction B". The specific activity of 
fraction B was fourteen-fold greater than that of fraction A, 
as displayed below: 
AMOUNT OF SPECIFIC YIELD (%) 
PROTEIN ACTIVITY UNITS 
(mg) units/mg 
Untreated 
Conditioned 100 769 76900 (100) 
Medium 
(Bowes/sf) 
Fraction A 50 6290 314500 (409) 
Fraction B 0.75 90416 67812 ( 88) 
(Peak 2 from 
Gel-filtration 
column) 
Note that in terms of yield, fraction B represented - 20% of 
the total number of inhibitory units in fraction A. The 
specific activity of fraction B was - 115-fold greater than 
that of the starting material, and 14-fold greater than that 
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of fraction A. The amount of protein represented by fraction 
B was - 0.75% of that present in the starting material. 
Fraction B appeared to be relatively heat stable. Over 50% of 
the inhibitory activity was retained following a period of 
heating for 2 hours at 70°C in the presence of 1 M acetic 
acid, as shown in Chart 16 below: 
Unheated 
CHART 16 
SPECIFIC ACTIVITY 
OF BOWES/SF 
FRACTION B 
Heated at 70°C for 2 hrs 
110 000 units/mg (100%) 
59 ooo units/mg (54%) 
An aliquot of Fraction B containing 20 µg of protein was 
heated at 70°C for 90 minutes. The sample was then 
lyophilized, as was a control 20 µg that had not been heated. 
Both the control and the heated material were tested in the 
UCT-BR-1 microtiterplate assay. 
The next question that was addressed was that of the 
reversibility of the growth inhibitory effect. UCT-BR-1 cells 
were seeded in a microtiter plate in the presence of RPMI-10 
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medium containing a concentration of Fraction B that was able 
to inhibit 3ff-thymidine incorporation by 40-50%. At various 
times, the MDGIF was removed from the UCT-BR-1 cells and was 
replaced with fresh medium. These indicator cells were 
therefore in contact with the growth inhibitor for increasing 
periods of time ranging from 6 to 90 hours. The results of 
this assay are displayed below {Chart 17). 
DURATION OF EXPOSURE TO 
MDGIF ELUTED FROM 
BIO-GEL P-60 COLUMN 
(FRACTION B) 
6 hours 
24 " 
55 " 
70 
" 
90 
" 
CHART 17 
Control counts were 22082 + 1300 
*NS= Not significant 
% INHIBITION 
2 NS* 
15 p<0.005 
55 p<0.005 
70 p<0.005 
70 p<0.005 
p values were determined by Student's t-test. 
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This data demonstrated that the effects of the MDGIF on 
UCT-BR-1 cells were fully reversible after 6 hours and were 
almost completely reversible after 24 hours. The% inhibition 
after 24 hours incubation in MDGIF was minimal (15%) but was 
nevertheless statistically significant. However, the growth 
inhibitory effects were entirely irreversible after longer 
exposure periods. 
Previous preliminary experiments that utilized hydrophobic-
interaction chromatography (phenyl-sepharose) had indicated 
the active MDGIF to be a relatively hydrophobic molecule. 
Further investigations demonstrated that the growth inhibitory 
activity could be retained on reverse-phase HPLC columns and 
would elute in the presence of organic solvents such as 
acetonitrile. This behaviour was known to be a feature of 
many previously characterized growth factor polypeptides, and 
reverse-phase HPLC had subsequently proved to be an important 
tool in their purification (13,38,62). For these reasons, and 
because of the apparent stability of the active MDGIF, the use 
of reverse-phase HPLC as a possible means of purification of 
the growth inhibitor was investigated. Fraction B was diluted 
in a relatively polar solvent and was loaded onto a 
semipreparative reverse-phase HPLC column (see Chart 18). 
Following this step, a linear acetonitrile gradient was used 
to elute material from the column. 
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This gradient yielded the absorbence profile (at 280 nm) as 
well as the biological growth inhibitory profile that is 
displayed in Chart 18. One major peak of growth inhibitory 
activity was found. This comprised fractions 20, 21, 22, 23 
and corresponded to material which eluted at - 62 to - 74% 
acetonitrile. No inhibitory activity was present in 
equivalent fractions from an identical blank gradient, run 
under the same conditions. 
The fractions containing the growth inhibitory activity were 
pooled and lyophilized. This pool, designated fraction c, 
contained only - 0.07 mg of protein. However, the specific 
activity was no greater than that of fraction Band in most of 
the repeat analyses that were performed, the specific activity 
was much less than that of fraction B, being usually of the 
order of -11000 units per mg protein. Furthermore, the 
inhibitory material from the HPLC appeared unstable; the 
specific activity of the lyophilized fraction c decreased 
significantly over fairly short time spans (2-3 weeks) • 
• Reverse-phase HPLC, using the conditions described above, 
therefore did not appear to be a suitable strategy for further 
characterization of the Bowes/sf growth inhibitor. 
Contd./143 
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CHART 18 
HPLC ANALYSIS OF FRACTION B 
Chromatography of the MDGIF on a C18 reverse-phase HPLC system demonstrated a major inhibitory 
peak eluting at -65% acetonitrile. The data from two individual chromatograms is displayed (Runs 1 
and2). 
The active fractions, consituting Fraction B, from the Bio-Gel 
P60 column were pooled and diluted 1 to 1 with distilled 
water. The final acetic acid concentration of the active pool 
therefore amounted to O.SM. Acetonitrile (Waters HPLC grade) 
and tri-fluoroacetic acid (TFA) were added to give final 
concentrations of 5% (v/v) and 0.05% (v/v) respectively. 
A Waters semi-preparative reverse-phase C18 (octadecylsilane) 
HPLC column was used. This column had an internal diameter of 
7.8mm and a length of 30cm. The column was first equilibrated 
with Solvent A (O.SM acetic acid, 5% acetonitrile, 0.05% TFA, 
pH 2.2) for at least 1 hour. The sample (usually having a 
volume of 100ml or more) was loaded onto the column through 
the solvent inflow channel, at 1 ml/min. When loading was 
completed, the column was washed with solvent A at 1 ml/min 
for one hour. A linear acetonitrile gradient from 5% to 75% 
was then run at 1% per minute, using a flow rate of 1 ml per 
minute. Two solvents were used to create the gradient; 
these were Solvent A (the formulation of which is given above) 
and Solvent B, which was 100% acetonitrile containing 0.05% 
TFA. 
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CHART 18 contd 
Whilst the acetonitrile gradient was being run, 3ml fractions 
were collected until the gradient was completed. This would 
happen at fraction 24. Thereafter a further 10 x 3.0 ml 
fractions were collected under isocratic conditions, during 
which the acetonitrile concentration was held constant at 75% 
(v/v). 
For assay purposes, 0.5ml aliquots were removed from each 
fraction (1 to 34 inclusive) and lyophilized. The remaining 
fractions were diluted 1 to 1 with distilled water, in order 
to lower the final acetonitrile concentration, and then were 
stored at 4°C until the results of the assay were known. The 
active fractions were then pooled and lyophilised. 
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CHART 18. 
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from RP-HPLC .. 
j I I I I 
Cts· HPLC 
0 
5 10 15 20 25 30 35 
Fraction Number 
-140-
CHART 18 
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CHART 19 
Autoradiograph of 15% SDS-PAGE of 125/-/abe//ed Fraction C from the RP-HPLC column. The sample 
was electrophoresed in two adlacent tracks. 
12sr-fraction c was prepared using the iodogen procedure (see 
appendix). A specific activity of 4.4 x 106 cpm per µg of 
protein was achieved. 
11 ng of 12sr-fraction C ( 48000 cpm) was mixed with 20µg of 
non-iodinated ("cold") Fraction Cina total volume of 10 µl. 
16µ1 of sos-sample buffer containing buffer containing 
beta-mercapto-ethanol (2-4%) and 2% sos was added and the 
sample was boiled for 2 minutes. 
The sample was electrophoresed in 2 adjacent tracks on a 
sos-polyacrylamide gel that utilized a 15% resolving gel and a 
4% stacking gel. Low molecular weight markers (Pharmacia) 
were run in tracks adjacent to that of the sample. 
The gel was stained with Coomassie Blue, and was then dried 
and subjected to autoradiography using Kodirex X-ray film (1 
K0,5UT) at -20°c for seven days. 
m.w. = Molecular Weight 
kd. = Kilodaltons 
m.w. 
kd. 
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CHART 19 
15 % SOS- PAGE 
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DISCUSSION 
The experiments outlined in this Chapter demonstrated that the 
specific activity of the Bowes/sf growth inhibitor could be 
enhanced -115-fold by processes involving membrane 
ultrafiltration and concentration as well as by acetic acid 
extraction and gel filtration chromatography. The significant 
increase in the specific activity was explicable by one of 
several possible processes: (a) enrichment of the growth 
inhibitory molecule (or molecules) in the preparation (b) 
activation of latent inhibitory materials (c) selective 
removal of factors which interfered with the growth inhibitory 
potential of the MDGIF. It was likely that more than one of 
these above processes contributed to the enhancement of the 
specific activity. If only the first process operated, one 
would not expect to have obtained an increase in the total 
number of inhibitory units (i.e. the yield) as occurred in the 
preparation of fraction A. 
There was a substantial fall in total yield following the 
gel-filtration chromatography. This was most likely a result 
of a decision not to examine the apparently higher molecular 
weight forms of the growth inhibitor. 
What of the identity of the inhibitor? Listed in point form, 
the major characteristics of the inhibitory material were as 
follows: 
(i) 
-144-
It was a macromolecule with a molecular weight in 
excess of 10000 daltons. 
(ii) It was both acid-soluble and acid-stable (in 1 M 
acetic acid pH 2.5). 
(iii) It was fairly heat stable at 65°C in the environment 
of the untreated conditioned medium as well as in 
the presence of lM acetic acid. 
(iv) The molecule was sensitive to trypsin and therefore 
appeared to be a protein. 
(v) Protein constituted about 18% of the dry weight of 
the material secreted by the Bowes/sf line. 
(vi) When chromatographed on a gel-filtration column, the 
major growth inhibitory fractions eluted with an 
apparent molecular weight in the 20 - 25000 dalton 
range. 
(vii) It was possible to enhance the specific activity of 
the growth inhibitor by a process of 
ultrafiltration/concentration, acid extraction and 
gel-filtration chromatography. 
(viii) 
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Analysis of the data suggested that activation of 
previously latent material might well play a role. 
There was a latent period between the addition of 
the growth inhibitor and observed morphological 
changes and growth inhibitory effect. This latent 
period was of at least one to two days duration. 
Furthermore, the growth inhibitory effect was 
reversible if the inhibitor was present for less 
than 24 hours and was then replaced by fresh medium. 
(ix) The inhibitor was not an interferon. 
(x) Biologically active TGF-~ was detected in fractions 
eluted from hydrophobic exchange columns. TGF-~ is a 
25000 dalton acid-stable growth regulatory 
polypeptide (76) with growth inhibitory effects, 
especially on breast tumour cells (139). Purified 
TGF-~ had some growth inhibitory actions in the 
UCT-BR-1 assay, but was unable to achieve the major 
degree of inhibition demonstrated by the MOGIF 
preparation. 
The material which eluted from the gel-filtration column 
(fraction B) was not yet pure. This judgement was based on 
the presence of numerous protein bands on SOS polyacrylamide 
gel electrophoresis (SOS-PAGE) of MDGIF preparation (Results 
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not shown). The possibility therefore existed, at least in 
principle, of obtaining inhibitory material of even greater 
specific activity. The decision to use reverse-phase HPLC to 
this end was based upon (i) the relative success ascribed to 
this approach in the identification of growth factors (ii) the 
apparent hydrophobicity of the growth inhibitor as assessed by 
preliminary qualitative experiments that utilized both 
hydrophobic-interaction chromatography and reverse-phase HPLC. 
However, reverse-phase HPLC chromatography of the growth 
inhibitor was unsuccessful in that it failed to enhance the 
inhibitory activity of the MDGIF preparation. There were 
several possible reasons for this failure. These included (i) 
partial inactivation of the growth inhibitor in the fairly 
harsh conditions used in reverse-phase HPLC (ii) separation of 
distinct molecular species, each with inhibitory activity, by 
the chromatographic procedure i.e. there might well have been 
multiple inhibitors, some of which either eluted prematurely 
under the isocratic loading conditions, or remained adherent 
to the column even in the presence of the non-polar solvent. 
Even the major inhibitory fraction which eluted from the 
RP-HPLC contained several molecular species. An 
autoradiograph of an SOS-PAGE of "Fraction C" is displayed in 
Chart 19. 
The presence of biologically active TGF-P in the inhibitory 
fractions which eluted from hydrophobic-interaction columns, 
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as well as the subsequent inability of purified TGF-~ to fully 
reproduce the inhibitory spectrum of the MDGIF, provided 
circumstantial evidence that more than one inhibitor might 
have been present. Furthermore, multiple inhibitory peaks 
were detected in the gel-filtration chromatography of MDGIF 
preparation. Although these peaks may have represented 
aggregated or multimeric forms of a single molecular species, 
as was suggested earlier, they may have been a result of 
multiple distinct molecular forms. 
In summary therefore, it was observed that the human cell line 
Bowes/sf, derived from a melanoma, (a tumour of neural crest 
origin) was able to proliferate in the complete absence of 
either serum, exogenous polypeptide growth factors, steroids 
or thyroid hormones. The Bowes/sf conditioned medium was 
growth inhibitory to a number of transformed human epithelial 
cell lines, especially a breast carcinoma UCT-BR-1. This 
inhibition followed a latent period of 1-2 days and was 
essentially irreversible after periods longer than 24 hours. 
Furthermore, inhibition occurred in the presence of 10% fetal 
calf serum which is rich in growth stimulatory factors. 
Additional experiments indicated that the inhibitory effect 
was due to a trypsin-sensitive, heat- and acid-stable 
polypeptide (or polypeptides) that was not a member of the 
interferon family. 
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The responsible polypeptide(s) appeared to have a molecular 
weight(s) in the 20 - 25000 dalton range. There was also 
evidence which indicated activation of previously latent 
growth inhibitory factor(s) during the characterization. 
At least one of the factors was identified as TGF-P (140-142), 
an acid-stable polypeptide that is now known to be a major 
autocrine inhibitor of breast carcinoma cells in vitro and in 
vivo (139,143). Furthermore TGF-P is produced in an inactive 
high molecular weight form that is subsequently activated 
either by acid conditions or by limited proteolysis (140,142). 
Besides breast carcinoma cells, TGF-P is known to inhibit 
numerous other cells of epithelial origin. However, 
non-epithelial cells generally remain either unaffected by 
TGF-P or are stimulated by this growth factor (140,142). 
TGF-P thus is a prototype of a bifunctional growth regulatory 
polypeptide that can either stimulate or inhibit the target 
cells, depending on the nature of the cell being studied and 
the presence or absence of other factors. TGF-P belongs to a 
family of regulatory polypeptides which appear to be derived 
from a single ancestral gene. Many of these polypeptides have 
inhibitory actions, and include inhibin (a gonadal factor 
which inhibits pituitary FSH release) and the Mullerian 
inhibitory polypeptide (140,142) which is responsible for 
regression of the female urogenital system in male embryos. 
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When the MDGIF phenomenon is examined in the light of the 
TGF-~ model, it is easy to conceive of a cell type that 
produces a factor that is either inactive or for which 
receptors are lacking on the producing cell, in this case the 
Bowes/sf line. Addition of this factor to the UCT-BR-1 cells 
produces growth inhibition because the UCT-BR-1 cells have 
functional receptors for the factor and in addition are able 
to activate the factor by, for example, producing proteases 
that cleave the factor at specific sites. In an alternative 
model, both the Bowes/sf and the UCT-BR-1 cells may have 
functional receptors but the nature of the response to 
receptor activation may be completely opposite in the two cell 
types. 
.~ 
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CHAPTER 4 
DIRECTIONS FOR THE FUTURE 
In this thesis, an attempt was made to characterise the 
phenomenon in which conditioned medium obtained from a 
malignant cell line of neural crest origin irreversibly 
inhibited the growth of transformed human epithelial lines. 
Although many important biological and biochemical features of 
the putative growth inhibitor were delineated, the molecule 
(or molecules) responsible for the inhibitory action was not 
isolated in a pure form. Furthermore, the description of the 
Bowes/sf inhibitor was obtained only within the constraints of 
certain clearly defined parameters. These included: 
(a) The response to the Bowes/sf medium and extracts 
thereof was defined as being inhibitory; this 
included either inhibition of cellular proliferation 
or inhibition of radiolabelled thymidine 
incorporation. Therefore, additional porantial 
responses to the Bowes/sf factor (e.g. expression of 
novel cell surface antigens) were not examined. 
(b) The inhibitory phenomenon was examined only in the 
presence of 10% fresh fetal calf serum. The latter 
is known to contain a multitude of growth factors. 
(c) The affected target cells were all transformed, 
aneuploid human epithelial cell lines. The most 
-151-
sensitive cell line appeared to be one derived from 
a metastatic breast cancer. 
(d) The Bowes/sf inhibitor was detected only on the 
basis of its biological activity and not on any 
antigenic or catalytic properties. 
It was essential to impose those constraints on the work 
performed for this thesis in order to allow the investigations 
to progress in a logical order. 
What direction should this work take in the future? There are 
two critical issues which would have to be addressed before 
full insight could be gained into the mechanism of action and 
the biological significance of the growth inhibitor. Both 
issues are equally important and are not mutually exclusive. 
Firstly, the inhibitor must be purified. Secondly, once 
purified, the interaction of the inhibitor with a number of 
target cells under a variety of different conditions must be 
studied. The first issue is essentially a biochemical problem 
that requires a reductionist approach. The second issue, is 
one in which the cellular interactions of the inhibitor 
require to be investigated. Using a simple analogy, the 
distinction between the two approaches could be compared to 
the difference between, on the one hand, isolating an enzyme 
in a pure form and, on the other, completely defining the 
metabolic pathway (with all its control mechanisms) in which 
that enzyme participates. Indeed, it has recently become 
apparent that growth regulatory polypeptides form an 
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interacting network, a network of complex variables in which 
the effect produced by the factor depends upon the presence 
(or absence) of other polypeptides as well as the nature of 
the responding cell (144). This broader, more universal 
approach, is essential in order to make progress in the field 
of cell and cancer biology. However, it would be very 
difficult to investigate the full biological significance of a 
growth factor without having pure material at hand. 
We therefore return to the first issue i.e. the problem of 
obtaining the growth inhibitory factor in pure form. Two 
questions must be answered. Why was it not possible to fully 
purify the active factor using the techniques described in 
this thesis? Furthermore, what are the new techniques that 
might be applied in the future in order to resolve this 
problem? 
One of the major problems encountered during the purification 
of growth factors has been the quantity of starting material 
that is needed. These are typically, either liters of 
conditioned medium (55) or several kilograms of cultured cells 
(75). The explanation lies in the ability of polypeptide 
growth factors to exert their biological effects at very low 
concentrations, often less than 10·12M. For this reason, they 
often exist only in trace amounts within biological sources. 
The above problem is compounded by the intrinsic 
hydrophobicity of many growth factor molecules, for this leads 
to unacceptable losses during the purification. Furthermore, 
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the protean nature of purely biological assays, especially 
those which are based upon cell growth kinetics, can make it 
extremely difficult to keep a systematic account of important 
parameters such as yields and specific activities. 
Some of the solutions to these problems are self-evident. 
There is therefore a need, as mentioned earlier, to 'scale-up' 
the purification protocol so that use is made of enormous 
quantities of starting material. In addition, losses can be 
minimized e.g. by using hydrophilic filtration membranes and 
siliconized glassware whenever possible. 
Because many of the assays for growth factors are 
operationally-defined biological assays, it is often useful to 
obtain a panel of antibodies, specific to known growth 
factors. These would help confirm whether or not a novel 
factor had indeed been isolated. 
There are a number of novel approaches which, in principle, 
could facilitate the isolation of a polypeptide growth factor 
which is normally present only in minute concentrations. 
Firstly, one could attempt to develop a specific monoclonal 
antibody by immunizing mice with crude starting material. 
Following the spleen cell fusion stage and the subsequent 
generation of the immortal hybrid line, the aim would be to 
detect positive clones by virtue of their ability to secrete 
antibodies which specifically block the action of the growth 
factor. In the special case of the Bowes/sf MDGIF, the 
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anti-MDGIF monoclonal antibodies would be defined by their 
ability to interfere with the growth inhibitory assay i.e. 
UCT-BR-1 cells would be seen to grow normally in the presence 
of MDGIF and specific antibody. Positive clones could then be 
expanded to generate large quantities of monoclonal antibodies 
which could be linked to an affinity support. It would then 
be feasible to purify the growth factor in a single step by 
means of affinity chromatography. The monoclonal antibody 
technique is therefore extremely useful because there is no 
requirement for purified antigen in order to generate the 
antibody. 
An alternative approach to the problem of identifying the 
factor would be to generate a cDNA library from Bowes/sf 
cells. The Bowes/sf cloned cDNAs could be inserted into 
expression vectors and then transfected into eukaryotic cells. 
Clearly, this is an enormous task, but it would be anticipated 
that a cDNA coding for the growth inhibitor should confer, 
upon the transfected cell, the property of synthesising MDGIF. 
In this manner it is possible, in principle, to identify the 
MDGIF cDNA without first achieving purification of the active 
polypeptide factor. 
-155-
Whatever the approach that is finally adopted, the ultimate 
and ideal aim of all the investigations would be to develop 
potential therapeutic applications for the inhibitory factor. 
It would be naive to assume that a single polypeptide factor 
might be of major clinical significance, but it is possible 
that such a polypeptide may well have a role when used in 
combination with a number of other cell growth factors. 
Even after a decade, the field of cell growth regulatory 
polypeptides remains in its infancy. Nevertheless, 
encouragement should be taken from the important insights 
which have been gained over this period. This field is one of 
the most rapidly expanding areas within modern cell biology. 
There is little doubt that this body of knowledge will have 
widespread future applications in such diverse areas as 
developmental biology, the enhancement of wound healing as 
well as in the control of malignancies. 
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APPENDIX 
1. CULTURE MEDIA AND SOLUTIONS 
RPM! 1640 medium (Gibco No. 074-1800) containing 2mM 
glutamine and 24mM bicarbonate, and Dulbecco's modified 
Eagle's medium (DMEM; Gibco No. 074-2100) containing 0.45% 
(w/v) glucose were purchased as powdered reagents from 
Gibco, reconstituted as recommended by the suppliers and 
adjusted to contain 500 units/ml of penicillin G, 0.2mg/ml 
of streptomycin and 0.06mg/ml of tylocine (Gibco). 
Fetal calf serum (FCS) was obtained as a gamma-irradiated 
product from the State Vaccine Laboratories, Pinelands, Cape 
Town. This was heat-inactivated (56°C, 30 minutes), sterile 
filtered (0.45 micron filter, Millipore HAWP04700) and 
stored as sterile 50 ml volumes at -20°c 
Tris-buffered saline (TBS) was made by dissolving NaCl, 8g; 
KCl 0.38g; Na2HP04 .2H20 0.125g; and Tris 
(hydroxymethylaminomethane) 3.0g in approximately 900 ml 
water. The solution was adjusted to pH 7.4 (at room 
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temperature) with 3M HCl, made up to 1000 ml with water and 
sterilized by autoclaving. This gave a final concentration 
of NaCl :137mM; KCl: SmM; Na2HP04 : 0.7mM and Tris: 
25.0mM. Double strength tris-buffered saline (2xTBS) 
contained the same constituents at twice the concentration. 
Phosphate buffered saline (PBS) pH 7.4 was made by 
dissolving NaCl, Bg; KCl, 0.2g, Na2HP04.2H20, 1.44g and 
KH2P04, 0.2g in approximately 900 ml of water. When 
dissolved, the pH was checked, and the volume was adjusted 
to 1000ml with distilled water. This gave final 
concentrations of Na+ 153mM; ~ 4.2mM; c1- 140mM; and 
inorganic phosphate 9.6mM. The solution can be sterilized 
by autoclaving. 
Versene Buffer. This was prepared by dissolving NaCl, 8g; 
KCl, 0.2g; Na2HP04.2H20, 1.14g; KH2P04, 0.2g and Na2 EDTA 
0.26g in 900ml of distilled water and then, when all 
components were dissolved, adjusting the volume to 1000ml. 
The solution was sterilized by autoclaving. 
final concentration of Na+ 151mM; ~ 4.2mM; 
inorganic phosphate 7.9mM and EDTA o.amM. 
This gave a 
c1- 140mM; 
Trypsin solution. Working solutions were prepared from a 
stock solution of 0.5% w/v trypsin (Difeo 1:250) in lmM HCl. 
Phenol Red (Flow Laboratories) was added to the stock 
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solution: 1 ml of 0.5% Phenol Red in 500 ml of trypsin 
stock. The stock solution was sterilized by passage through 
a 0.45 micron Millipore filter and was stored frozen, in 
50ml volumes at -20°c. 
Working solution 1: 0.25% trypsin with EDTA was prepared by 
mixing equal volumes of 0.5% trypsin and 2xTBS. After 
mixing, 1 ml of 2% Na2 EDTA (made up in TBS) was added to 
each 100ml solution to give 0.25% trypsin, 0.6mM EDTA in TBS. 
Working solution 2: 0.05% trypsin with EDTA was prepared by 
mixing equal volumes of 0.5% trypsin stock solution and 
2xTBS. The mixture was then diluted 1:5 with Versene buffer 
to give 0.05% trypsin, 0.6mM EDTA in tris-phosphate-buffered 
saline. 
Tris-saline ultrafiltration buffer was made by dissolving 
NaCl, 8.0g and tris (hydroxymethylaminomethane), 3.0g in 
900ml distilled water and then adjusting the pH to 7.4 with 
HCl. The solution was then made up to 1000ml with distilled 
water and was sterilized by autoclaving. This gave final 
concentrations of NaCl : 137mM and tris: 25mM. 
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2. CELLS 
The cells used in this study are described briefly in the 
paragraphs that follow. The prefix "UCT-" indicates that 
the cells are maintained as a continuous cell line that was 
established at the University of Cape Town, in this 
laboratory, largely due to the efforts and expertise of 
Professor E.L. Wilson. "RPMI-10" or "RPMI-15" is the 
terminology used to indicate the percentage supplementation 
with fetal calf serum namely 10% and 15% FCS respectively in 
these two examples. 
UCT-BR-1 (130) 
This line was established in 1977 from a biopsy of an 
osseous metastasis of a primary carcinoma of the breast. 
The cells grow as an adherent monolayer with a 
characteristic polygonal, individual morphology and an 
equally characteristic social tendency to aggregate into 
acinar-like cell formations on the subtratum (Fig. 1). The 
cells are aneuploid and grow in RPM! supplemented with 10% 
fetal calf serum (RPMI-10) and antibiotics. The cells have 
a doubling time of approximately 60 hours. UCT-BR-1 
responds to estrogens but not to progesterone. The cells 
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have a clear growth requirement for insulin and other growth 
factors that are present in serum and that are removed by 
treatment with activated charcoal (130). In routine use, 
the cells are released from the substratum using trypsin 
working solution 2 and are reseeded at a density of between 
3 and 6x104 cells/cm2. 
UCT-CA-2 was established from a metastatic carcinoma removed 
from a thoracic vertebra of a 40 year old male. A 
bronchogenic carcinoma was considered to be the most 
probable primary site, but this was not confirmed. The 
cells grow as an adherent monolayer with a doubling time of 
24 hours in RPMI-10. 
UCT-50-1 was derived from a lymph node metastasis; the 
primary was a carcinoma of the lip. The line is maintained 
in RPMI-10. 
A431 cells were obtained from Dr. E. Reich of the 
Rockefeller University, New York, as a subculture of an 
epidermoid carcinoma line (131) that had been shown by wrann 
and Fox (132) to be abundantly endowed with epidermal growth 
factor receptors. 
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The cells are maintained as adherent well-spread monolayer 
cultures in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with FCS. 
Trypsin, Working Solution 1, was used to release UCT-CA-2, 
UCT-SQ-1 and A431 cells from the substratum. 
Bowes/sf cells 
The Bowes melanoma cell line was originally established by 
Dr. George Moore, of Denver, Colorado, U.S.A. from a biopsy 
of a metastatic melanoma and is referred to, in the original 
reports, as RPMI-7272. A subculture of this line was 
provided by Dr. E. Reich of the Rockefeller University and 
was adapted by Professor E.L. Wilson to grow in serum-free 
medium. The line originally introduced into the laboratory 
and used in my initial studies was found to be heavily 
contaminated with mycoplasma. The method of mycoplasma 
detection, and the protocol used for the elimination of the 
mycoplasma is described in detail in a later section. 
The cell line used in this thesis is called Bowes/sf 
(serum-free) to distinguish it from the serum-dependent 
Bowes line. I Bowes/sf grows as a loosely adherent monolayer 
with a doubling time of 5 1/2 days. The cells are clearly 
less well-spread than the serum-dependent cells and have a 
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characteristic refractile, rounded morphology. Addition of 
serum to the cultures causes the cells to revert to the 
well-spread appearance of the original serum-dependent line. 
Cultures were maintained in RPMI-1640 medium supplemented 
with antibiotics and were passaged by tapping the flask (to 
dislodge cells), collecting the detached cells by light 
centrifugation (400g; 5 minutes at room temperature) and 
reseeding at a density of Jx105/cm2. 
The cells currently used to produce the growth inhibitor 
described in this thesis are free of mycoplasma, as 
established by two independent methods. 
Maintenance of cell lines in culture 
Generally speaking, cells were fed as frequently as the 
cultures seemed to require it. This depended upon the 
growth rate of the cells, the rate at which they liberated 
acid metabolites (sufficient to change the phenol red 
indicator in the medium from red to yellow) and the 
appearance of the cultures under phase-contrast microscopy. 
All cell lines were kept as stocks frozen in liquid 
nitorgen. As far as possible all cells were used from 
expanded stocks that had been frozen at the same passage 
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number. In a typical case, cells from a single tube would 
be thawed, expanded and re-frozen to give a set of 
sub-cultures that provided a supply of experimental cells 
that had not drifted, genetically, too far from the 
reference culture. 
Cells were frozen according to the following standard 
protocol: after detachment, the cells were washed once with 
complete medium containing 10% FCS (to neutralize any 
remaining trypsin) or with serum-free medium in the case of 
the Bowes/sf cells. The cells were then re-suspended at an 
approximate concentration of 106/ml in 1 ml of complete 
medium with serum containing 10% w/v of dimethyl sulfoxide 
(DMSO). The cells were then immediately transferred into 
freezing tubes (Nunc Cat. No. 363401) and placed on ice. 
The freezing tubes were placed in an automatic cell-freezer, 
programmed to freeze at the rate of 5°C/min to a temperature 
of -26°C. They were held at this temperature for twelve 
minutes and then frozen rapidly to -7o0c. At this stage, 
the tubes could be transferred to liquid nitrogen storage 
tanks. 
Cells were thawed rapidly by agitating the tube manually in 
a 37°C water bath until the last vestige of ice had melted, 
whereupon the contents of the tube were poured into a 10cm 
dish containing 10ml of complete medium. After six hours 
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(i.e. when the cells had adhered sufficiently to stand 
gentle washing) the monolayers were rinsed with warm (37°C) 
medium, re-fed and returned to the incubator. 
Cells were counted with a haemocytometer or with an 
electronic cell counter (Coulter Electronics: "Model ZB r") 
that had been calibrated against a haemocytometer and 
according to the manufacturers' instructions. 
3. COLLECTION OF BOWES/SF CONDITIONED MEDIUM 
Bowes/sf cells were maintained at 37°C and in a 95% air, 5% 
CO2 mixture as confluent monolayers (approximately 5x107 
cells/cm2) in 150cm2 flasks: (Costar: Cat. No. 3150) 
containing 100 ml of serum-free RPM! medium supplemented 
with 2mM glutamine, 24mM bicarbonate and antibiotics. Every 
48h, the conditioned-medium (now appreciably acid) was 
decanted and replaced with fresh medium. 
Provided the flasks did not become infected and the cells 
remained healthy, each flask yielded useful conditioned 
medium for several weeks to months. The natural tendency 
for the cells to detach when available plate substratum 
became limiting prevented loss of cultures from super-
confluence. 
-166-
The conditioned medium was centrifuged (400g; 4°C; 15 min) 
to sediment detached cells and a small amount of debris, 
after which the medium was filtered sequentially through an 
8 micron filter (Millipore No. SCWP) and a hydrophilic 0.45 
micron filter (Durapore HVLP Millipore). The clarified 
medium was made to 0.1% (w/v) with respect to sodium azide 
and was stored at 4°C. 
Since 8 to 10 flasks of cells were maintained, approximately 
3 litres of conditioned medium was prepared each week. 
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4. CONTROL OF MYCOPLASMA CONTAMINATION 
Detection of mycoplasma contamination 
Two methods were used to detect mycoplasma contamination of 
cell cultures. 
(A) DNA fluorochrome stain (Hoechst Stain No. 33258) 
according to the method of Chen et al. (133). This 
stain was purchased in the form of a kit which 
contained both positive and negative control slides 
(Flow Laboratories, Cat. No. 30-100-00). 
Briefly, Bowes/sf cells were seeded sparsely on four 
chambered glass slides (Lab-Tek (R) slides; Cat. No. 
4804; Lab-Tek products; Division Miles Laboratories 
Inc., Naperville, Illinois 60540) in RPMI-10 and were 
allowed to settle and spread overnight. The next day 
the slides were fixed with Carney's fixative, (25% 
glacial acetic acid, 75% absolute methanol) according 
to the manufacturer's instructions and were then 
stained. This was followed by repeated distilled water 
washes. Coverslips were mounted after the slides had 
been covered with mounting medium comprising citric 
acid monohydrate 4662mg/L, disodium phosphate 8247 
mg/L, glycerol 500ml/L. Slides were examined carefully 
-168-
FIGURE 2 
FIGURE 3 
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under 400x magnification using an Olympus BH-2 
reflected light (Epi-illumination) fluorescence 
microscope with an ultraviolet light excitation filter. 
The dichroic mirror and barrier filter were chosen 
according to the emission peak of Hoechst Stain 33258 
(490-500nm). The typical appearance of 
mycoplasma-contaminated cells is shown in Fig. 2. 
(B) Mycotect R Assay (Bethesda Research Laboratories, Cat. 
No. 95765A). This assay derives from the knowledge 
that mycoplasmas contain the enzyme adenosine 
phosphorylase, and that this enzyme is lacking in 
mammalian cells. Adenosine phosphorylase converts 
6-methylpurine deoxyriboside (6-MPDR), a non-toxic 
analogue of adenosine, into two products, 
6-methylpurine and 6-methylpurine riboside, both of 
which are toxic to mammalian cells (134). Mammalian 
cells that are contaminated with mycoplasmas will 
therefore fail to grow in 6-MPDR (Mycotect R). 
This assay was performed on Bowes/sf cells that had 
been seeded sparsely in 24-well plates (Costar No. 
3524) in RPMI-10. Mycotect R (6-MPDR) was added to the 
medium in the wells to give the following final 
concentrations: o, 15 uM/L and 30 uM/L. After 48-72 
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hours in culture, the cells were released by 
trypsinization and were counted using a haemocytometer. 
Both the DNA fluorochrome stain and the Mycotect R were 
performed on Bowes/sf cells that had been grown in 
antibiotic-free medium for 72 hours prior to seeding 
for the assay. 
Decontamination of mycoplasma-infected cells 
Bowes/sf cells were decontaminated by being repeatedly 
passaged through nude mice. 2-sx106 Bowes/sf ·cells were 
injected subcutaneously into the interscapular region of 
congenitally athymic nu/nu ("nude") mice that were 
maintained in a sterile pathogen-free environment. The 
resulting tumours were removed, and were cut into small 
pieces which were inserted subcutaneously via skin incisions 
into another group of nude mice. 
After three such passages, through nude mice, the tumours 
were removed sterilely from the mice and were minced finely 
wth sterile scissors. This was followed by enzymatic 
digestion of the tumour, first in trypsin (working solution 
1, 0.25%) for 15 min at 37°C, followed by collagenase 
(Sigma, type IV, Jmg/ml in DMEM, 5% FCS) for several hours 
at 37°C. The dispersed tumour cells were pelleted by 
Contd./172 
Bowes/sf cells, prior 
to nude mouse injection 
Bowes/sf cells 
passaged in nude mice 
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MYCOTECT CONCENTRATION (uM/L) 
0 15 30 
6.87 3.46 2.63 
6.66 6.91 6.80 
The above values, when multiplied by 105 give the cell 
counts of Bowes/sf cells in the Mycotect assay. Each value 
is the mean of duplicate counts. When grown' in Mycotect, a 
reduced cell count (relative to the control) indicates the 
presence of mycoplasmas. 
TABLE 1 
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centrifugation and were plated in 35 mm petri dishes (Falcon 
No. 3001) in RPMI-10. Stocks of Bowes cells thus obtained 
were expanded and were tested for the presence of 
mycoplasmas using the two methods described above. THEY 
WERE FOUND TO BE FREE OF MYCOPLASMA CONTAMINATION (See 
Figure 3 and Table 1). 
Mycoplasma-free Bowes cells were then adapted to grow in a 
serum-free environment. This was achieved simply by 
omitting serum from the culture medium. The Bowes cells 
adapted fairly rapidly and this adaptation was associated 
with a change in morphology of the cells. They became 
rounded up, but remained attached and thus they took on the 
typical appearance of Bowes/sf cells. These mycoplasma-free 
Bowes/sf cells were used for the definitive purification of 
the MDGIF. 
5. ULTRAFILTRATION METHODS 
The inhibitory material was present in Bowes/sf conditioned 
medium at a very low concentration and some degree of 
enrichment was required initially before purification could 
reasonably proceed. At several stages during the various 
purification procedures used, it was again essential to 
concentrate the MDGIF. This could conveniently be achieved 
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by ultrafiltration, a procedure that also provided a 
convenient estimate of the approximate molecular weight of 
the inhibitory factor. 
The different forms of ultrafiltration apparatus used 
included: 
(a) A hollow fibre concentrator (Amicon Model CH3) fitted 
wwith an HlP5 "Diafiber" membrane cartridge (nominal 
molecular weight cutoff 5000 daltons) and operated with 
a 400ml/min peristaltic pump. Pressure in the 
cartridge is controlled by means of a variable 
back-pressure valve. 
(b) Stirred presure cells, of which 3 models are available. 
Model 
Amicon Model 402 
Amicon Model 202 
Amicon BMC micro-
ultrafiltration system 
Volume 
400ml 
200ml 
100ml 
Diameter of 
Ultrafiltration 
membrane 
76mm 
62mm 
25mm 
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The stirred cells are operated with Anticon "Diaflo" 
ultrafiltration membranes. These membranes are designated 
UM-2 (1000 dalton cutoff), PM-10 (10 000 dalton cutoff) and 
YM-10 (a more hydrophilic membrane with a 10 000 dalton 
cutoff). 
(c) Millipore "Minitan" (Cat. No. XX42l concentrator that 
utilizes a tangential flow procedure. Five membranes 
(type PTGC) each with a nominal molecular weight limit 
of 10 000 daltons were used. During any "run", 6 to 7 
liters of conditioned medium would be concentrated to 
about 700-SOOmls over about 10-15 hours. 
6. THE MICROPLATE ASSAY FOR MDGIF 
All incubations were performed at 37°C in an atmosphere of 
5% CO2 and 95% air. 
UCT-BR-1 cells wre seeded at 1.5 to 2x104 cells per well of 
a 96-well flat-bottom tissue culture plate (Falcon Microtest 
II, No. 3040). After an overnight incubation, the seeding 
medium was aspirated and was replaced with 0.1ml of the 
medium to be tested. The plates were then returned to the 
incubator. After 54 hours, each well received 0.01ml of 
RPM! containing [3H]-thymidine (Amersham, TRK 61) at 
20µCi/ml and O.Olmg/ml of unlabelled thymidine. This 
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provided a final concentration, in each well, of 2µCi/ml of 
[3H]-thymidine (3H-TdR) and lµg/ml of non-radioactive 
thymidine. After a further 18 hours (i.e. after a total of 
72 hr of exposure to the inhibitory factor) the cells were 
harvested and the incorporated radioactivity was counted. 
This was performed as follows: 
The microplates were removed from the incubator and the 
medium was gently aspirated from each well. The adherent 
cells were then washed by adding, in two successive cycles, 
approximately 0.2ml of pre-warmed (37°C) serum-free RPMI to 
each well and aspirating it. The cells were then released 
from the substratum by adding, to each well, 0.05ml of 0.25% 
trypsin (Working solution 1) containing 0.25M alpha-methyl-
D-mannoside. The plate was then incubated at 37°C for 20 
minutes and was shaken vigorously on a rotary plate shaker 
to release the cells. The radioactive cells were then 
harvested onto glass-fibre filter sheets (Titertek R, Cell 
Harvester filters, Flow Laboratories) using a multiple 
semi-automatic cell harvester that was constructed in this 
laboratory. The glass-fibre filter sheets were dried in a 
45°C oven for several hours. Each circular area, containing 
the harvested cells from an individual corresponding well, 
was pressed out into a counting vial and was assayed for 
tritium content by liquid scintillation counting after the 
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addition of 3.0ml of Insta-gel R (United Technologies, 
Packard). 
Inhibitory activity in test samples was measured as the 
percentage inhibition of 3H-TdR uptake relative to that of 
control cells (i.e. cells exposed to medium alone). This is 
calculated as follows: 
% Inhibition = (Control cpm - test cpm) x 100 
control cpm 
Liquid scintillation counts were measured with either a 
Packard Tri-Carb Model 3380 or a Beckman LS3800 counter. 
7. CHROMATOGRAPHY 
Column chromatography was performed using established 
techniques. Details of the chromatographic condition for 
each run are described in the text or in the figure legends. 
The following chromatographic media were prepared and used 
according to the manufacturers instructions: 
A. Bio-Gel P-60, fine, 100-200 mesh (wet). Fractionation 
range 3000 - 60000 daltons. (Bio-Rad cat. No. 1501640). 
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B. Bio-Gel P-6, fine, 200-400 mesh (wet). Fractionation 
range 1000 - 6000 daltons. (Bio-Rad Cat. No. 1500750). 
c. Bio-Gel P-6DG, Desalting Gel, 80-170 mesh (wet). 
Fractionation range 1000 - 6000 daltons. (Bio-Rad Cat. 
No. 150-0738). 
D. CM52 carboxymethyl cellulose cation exchanger. 
Microgranular, pre-swollen form (Whatman, Cat. No. 
6876). 
E. SP - Trisacryl RM (UCB, cat. No. 2205-400). 
F. Phenyl-sepharose R CL-4B (Pharmacia Fine Chemicals, 
Cat. No. 17-0810-01). 
Columns were run either under a gravity-induced flow or with 
a peristaltic pump. Column effluents were monitored 
spectrophotometrically at 280nm using a Uvicord R 
ultraviolet absorptiometer detector unit type 8303A linked 
to a type 8301A control unit (UCB). The column effluent was 
collected in a series of tubes that would change by means of 
an automatic fraction collector: Ultrorac R (UCB) or 
Frac-100 (Pharmacia). 
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High Performance Liquid Chromatography 
The following columns were used: 
(i) For Reverse-phase procedures 
- uBondapak Cl8 (Waters) No. 27324, 3.9*mmx30cm. This is 
referred to in the text as an "analytical" column. 
- uBondapak Cl8 (Waters) No. 84176, 7.a*mmx30cm. This is 
referred to in the text as a "semi-preparative" column. 
(ii) For Ion-exchange procedures 
TSK-IEX-545 DEAE, 6*mmxl5cm (Toya Soda Manufacturing Company 
Limited, Japan). 
* All cross-sectional diameters are internal diameters. 
The HPLC system comprised the following components: 
A. Pump 1 (Waters Model 6000A solvent delivery system). 
B. Pump 2 (Waters Model M-45 solvent delivery system). 
C. Automated Gradient Controller (Waters Model 680). 
D. Spectrophotometer (Waters, Lamda-Max Model 480). 
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8. PROTEIN DETERMINATIONS 
These were performed by either one of three methods. 
A. Method of Lowry (135) 
B. OD280/0D260 method; this is based on the absorption of 
ultraviolet light by aromatic amino acids. The 
following formula was applied: 
Estimated protein concentration= (l.45xOD280nm) -
(0.74xOD260nm)mg/ml. 
c. Coomassie Blue G-250 Dye-binding Technique of Bradford 
(136). This is supplied as a commercial kit (Bio-Rad 
Cat. No. 500-0001 or 500-0002). The kit contains a dye 
reagent concentrate and a protein standard. The latter 
may be either bovine gamma globulin or bovine plasma 
albumin. 
Assays were carried out according to the manufacturers' 
instructions. 
The dye-binding technique was the most frequently used 
protein assay procedure in the thesis. It was always done 
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as a microassay procedure which typically detects protein in 
the 1 -25µg/ml range. The assay was read on a Unicam SP1800 
ultraviolet spectrophotometer at 595nm. Standard curves 
were plotted by means of a Hewlett-Packard 85 computer using 
a linear regression program. 
9. INTERFERON AND ANTI-INTERFERON 
Human lymphoblastoid interferon (IFN) was obtained by 
courtesy of Professor B. Schoub (National Institute of 
Virology, Sandringham, Transvaal). The IFN was derived from 
Namalwa cells infected with Sendai virus and the activity of 
the preparation had been determined as 16 000 i.u./ml. 
A sheep antiserum to human alpha IFN was obtained from Dr. 
K.C. Zoon, (NIH, Bethesda, Maryland, U.S.A.) while 
anti-IFN-beta was supplied by Dr. Jan Vilcek (NYU School of 
Medicine, New York). The anti-IFN-alpha contained 105 
neutralizing units/ml while the anti IFN beta contained 
2x105 neutralizing units/ml. 
Since preliminary experiments had shown that these antisera 
were directly toxic (for reasons unknown) to UCT-BR-1 cells 
in culture, it was decided to "desalt" the antibodies into 
phosphate buffered saline pH 7.4 (PBS) using gel-filtration 
chromatagraphy. For this purpose 2.4 mls of an anti-IFN 
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antibody preparation (consisting of a mixture of 2.1 mls of 
anti-IFN alwia and 0.3mls of anit-IFN beta) was 
chromatographed on a 20xl.2cm Bio-Gel P6 DG (Bio Rad) column 
previously equilibrated with PBS. The flow rate of the 
column was llmls/hour/cm2. 1ml fractions were collected. 
Only the void volume "peak" (lOmls) was pooled and was 
concentrated to 3mls on an Am.icon 8-Mc unit using a 25mm 
YM-10 'Diaflo' membrane. The 3 ml of retentate was 
sterile-filtered (for use in assays) using a Millex-GV 0.22 
micron sterile filter unit. 
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10. TYPE BETA TRANSFORMING GROWTH FACTOR (TGF-BETA) 
TGF-beta, purified from human platelets, was kindly supplied 
by Dr. Anita Roberts of the National Institutes of Health, 
Bethesda, Maryland. The TGF-beta sample was delivered in a 
reaction vial containing two micrograms of TGF-beta in 100 
ul of 4mM HCl with lmg/ml BSA(HB). This sample was diluted 
1 in 10 with HB giving 200 ng/lOOul TGF-beta. This was 
distributed in 50 microlitre aliquots into Cryotubes (Nunc 
Cat. No. 363401). Each aliquot therefore contained lOOng of 
pure TGF-beta. These were stored frozen at -20°c. 
11. IODOGEN METHOD 
1 mg Iodogen (Pierce Chemical Corporation) is dissolved in 1 
ml dichloromethane. 20 ul of this solution is added to each 
of several 12 x 75 mm glass tubes which are then rotated in 
a 37°C water bath until the solvent has evaporated. These 
"coated" tubes can be stored in a dessicator at 4°C. 
To a coated iodogen tube: 
Add 10 µl of a 0.25M sodium phosphate buffer, pH 7.5. 
Add 20 µl of protein to be iodinated. 
Add 5 µl of carrier-free Na12SI at 100 µCi/µl. 
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cover the tube and leave for 15 min at room temperature. 
Mix the contents of the tube at one minute intervals. At 
the end of the incubation, transfer the contents of the tube 
to the gel-filtration syringe. Wash out the iodogen tube 
with 70 µl of phosphate buffer. 
Separation of iodinated proteins from free 12sr: 
A Trisacryl GFOS gel (exclusion limit 3000 daltons) is used. 
This is packed into a 1 ml syringe and is washed with 0.25M 
phosphate buffer pH 7.5. Non-specific binding sites on the 
gel are blocked by addition of 100 ul of a 10 mg/ml bovine 
serum albumin (BSA) solution. 
After addition of the BSA, the syringe is spun at 800 rpm 
for 2 min. 
The iodinated solution is transferred from the coated tube 
to the Trisacryl GF05 syringe-column which is then 
centrifuged at 800 rpm for 2 min. to elute the iodinated 
protein. 
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